var title_f14_23_14704="Normal bowel gas pattern on plain abdominal radiograph";
var content_f14_23_14704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal bowel gas pattern on plain abdominal radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain abdominal radiograph&nbsp;shows a normal pattern with gas throughout nondilated loops of small and large bowel",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Deborah Levine, MD. Copyright &copy; Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14704=[""].join("\n");
var outline_f14_23_14704=null;
var title_f14_23_14705="Rx anal fissures";
var content_f14_23_14705=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Approach to patients with an anal fissure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 577px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Nitroglycerin ointment (0.4 percent) is commercially available in the United States (US). Nitroglycerine ointment (0.2 percent), topical bethanechol (0.1 percent), topical diltiazem (2 percent) and topical nifedipine gel (0.2 percent) are not commercially available products (US). These formulations can be prepared and dispensed by a specialty compounding pharmacy. The other commercially available formulation of nitroglycerin ointment (2 percent) contains a higher concentration of the active ingredient and should not be used.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14705=[""].join("\n");
var outline_f14_23_14705=null;
var title_f14_23_14706="Air cast";
var content_f14_23_14706=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Air cast for ankle immobilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 575px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The air cast (figure A) is easy to apply (figure B) and is appropriate for the immobilization of nondisplaced Salter I fractures of the distal fibula and ankle sprains.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: DJO, LLC. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14706=[""].join("\n");
var outline_f14_23_14706=null;
var title_f14_23_14707="MID CABG incisions";
var content_f14_23_14707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Surgical incisions used for minimally invasive CABG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Conventional CABG uses a long median sternotomy incision (A), while the incisions for minimally invasive CABG are small (5 to 7 cm) and include transternal (B), right parasternal (C) extending over the fourth and fifth costal cartilages, left parasternal (D) extending over the third and fourth costal cartilages, and limited thoracotomy (E).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Stanbridge RD, Hadjinikolaou LK, Cohen AS, et al. Ann Thorc Surg 1997; 65 (6 Suppl):S53.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14707=[""].join("\n");
var outline_f14_23_14707=null;
var title_f14_23_14708="CyA induced tubular injury";
var content_f14_23_14708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing cyclosporine-induced renal tubular injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph shows vacuolization of the proximal tubular cells (arrows) due to cyclosporine nephrotoxicity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14708=[""].join("\n");
var outline_f14_23_14708=null;
var title_f14_23_14709="Bortezomib: Patient drug information";
var content_f14_23_14709=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bortezomib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     see \"Bortezomib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Velcade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Velcade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4090502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may irritate the vein. It may burn the skin if the drug leaks from the vein when it is given. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691968",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat multiple myeloma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3406299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat amyloidosis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bortezomib, boron, mannitol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697825",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid multivitamins, natural products, and diet aids that have extra vitamin C.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696669",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid green tea and green tea extracts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Viral infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14854974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11168 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-61DB87C3C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14709=[""].join("\n");
var outline_f14_23_14709=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142137\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855139\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026823\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026825\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026824\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026829\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026830\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854974\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026827\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026834\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=related_link\">",
"      Bortezomib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_23_14710="Measles, mumps, rubella, and varicella virus vaccine: Pediatric drug information";
var content_f14_23_14710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Measles, mumps, rubella, and varicella virus vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29334?source=see_link\">",
"    see \"Measles, mumps, rubella, and varicella virus vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/20/14657?source=see_link\">",
"    see \"Measles, mumps, rubella, and varicella virus vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1433435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ProQuad&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10407944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Priorix-Tetra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2886917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine, Live Virus",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2886926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29334?source=see_link\">",
"      see \"Measles, mumps, rubella, and varicella virus vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Children 12 months to 12 years: One dose (0.5 mL). The first dose is usually administered at 12-15 months of age. If a second dose is needed, ProQuad&reg; can be used and is usually administered at 4-6 years of age; second dose may be administered before age 4 if needed, as long as &ge;3 months have elapsed since the first dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACIP recommendations: For children receiving their first dose at 12-47 months of age, either the MMRV combination vaccine or separate MMR and varicella vaccines can be used; however, the ACIP prefers administration of separate MMR and varicella vaccines as the first dose in this age group unless the parent or caregiver expresses preference for the MMRV combination. For children receiving the first dose at &ge;48 months or their second dose at any age, use of MMRV is preferred. The ACIP recommends that children with a personal or family history of seizures be vaccinated with separate MMR and varicella vaccines, as opposed to the MMRV combination vaccine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allow at least 1 month between administering a dose of a measles-containing vaccine (eg, M-M-R&reg; II) and ProQuad&reg;.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allow at least 3 months between administering a varicella-containing vaccine (eg, Varivax&reg;) and ProQuad&reg;.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1582151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ProQuad&reg;: Measles virus &ge;3.00 log",
"     <sub>",
"      10",
"     </sub>",
"     TCID",
"     <sub>",
"      50",
"     </sub>",
"     , mumps virus &ge;4.3 log",
"     <sub>",
"      10",
"     </sub>",
"     TCID",
"     <sub>",
"      50",
"     </sub>",
"     , rubella virus &ge;3.00 log",
"     <sub>",
"      10",
"     </sub>",
"     TCID",
"     <sub>",
"      50",
"     </sub>",
"     , and varicella virus &ge;3.99 log",
"     <sub>",
"      10",
"     </sub>",
"     PFU [contains albumin (human), bovine serum, chicken egg protein, gelatin, neomycin, sorbitol, and sucrose (&le;21 mg/vial)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1433437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2886927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Use entire contents of provided diluent to reconstitute vaccine. Gently agitate to mix thoroughly. Discard if powder does not dissolve. Use as soon as possible following reconstitution; administer by SubQ injection into the anterolateral aspect of the thigh or deltoid region of arm;",
"     <b>",
"      not for I.V. administration",
"     </b>",
"     . U.S. law requires that the date of administration, name of manufacturer, lot number, and administering person&rsquo;s name, title, and address be entered into patient&rsquo;s permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2886924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     Vaccine: Stable in a freezer for up to 18 months at temperatures between -50��C to -15��C (-58&deg;F to + 5��F). May store under refrigeration at 2&deg;C to 8��C (36&deg;F to 46��F) for up to 72 hours prior to reconstitution. Protect from light; use within 30 minutes following reconstitution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diluent: Store at under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) or at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2886918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To provide active immunity to measles, mumps, rubella, and varicella viruses (FDA approved in ages 12 months to 12 years)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination against measles, mumps, rubella, and varicella in healthy children 12 months to 12 years of age. For children receiving their first dose at 12-47 months of age, either the MMRV combination vaccine or separate MMR and varicella vaccines can be used. The ACIP prefers administration of separate MMR and varicella vaccines as the first dose in this age group unless the parent or caregiver expresses preference for the MMRV combination. For children receiving the first dose at &ge;48 months or their second dose at any age, use of MMRV is preferred.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F1582134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Also refer to Measles, Mumps, and Rubella Vaccines (Combined) (M-M-R&reg; II) and Varicella Virus Vaccine (Varivax&reg;) monographs for additional adverse reactions reported with those agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever &ge;38.9��C (&ge;102��F), irritability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Measles-like rash, rash, rubella-like rash, varicella-like rash, viral exanthema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Erythema, injection site reaction (including bruising, pain, soreness, swelling, tenderness)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Febrile seizures, rubella-like rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2886920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the vaccine including gelatin; known anaphylactic reaction to neomycin; individuals with blood dyscrasias, leukemia, lymphomas, or other malignant neoplasms affecting the bone marrow or lymphatic systems; concurrent immunosuppressive therapy; primary and acquired immunodeficiency states including HIV or a family history of congenital or hereditary immunodeficiency; cellular immune deficiencies; hypogammaglobulinemic and dysgammaglobulinemic states; active untreated tuberculosis; current febrile illness (&gt;38.5&deg;C); pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3871904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution with history of cerebral injury, seizures, or other conditions where stress due to fever should be avoided; reported incidence of fever (&ge;38.9&deg;C (&ge;102&deg;F) was 20%. Children 12-23 months of age have been reported to have a twofold-higher risk of developing febrile seizures with the use of the combination product MMRV compared to administration of MMR and varicella separately. Because it is uncommon for a child to have their first febrile seizure after 4 years of age, the ACIP recommends the use of the combination MMRV vaccine for children receiving their first dose at &ge;48 months or their second dose at any age. The ACIP recommends that children with a personal or family history of seizures be vaccinated with separate MMR and varicella vaccines, as opposed to the MMRV combination vaccine. Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever due to vaccines has been shown to decrease the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use caution in patients with thrombocytopenia and in patients who develop thrombocytopenia after first dose; thrombocytopenia may worsen. Defer vaccination at least 3 months after receiving blood and plasma transfusions or immune globulin; these products may interfere with immune response.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2886921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactic/anaphylactoid reaction should be available during vaccine use. Vaccine contains trace amounts of chick embryo antigen. Use caution in patients with history of immediate hypersensitivity/anaphylactic reactions following egg ingestion. Generally, the vaccine can be safely administered to persons with an egg allergy (CDC, 2011). Varicella virus transmission may occur; vaccinated individuals should not have close association with susceptible high-risk individuals (eg, newborns of women without positive history of varicella and all newborns &lt;28 weeks gestation regardless of maternal immunity, pregnant women without positive history of varicella, and immunocompromised persons) for 6 weeks following vaccination. While safety and efficacy of this combination vaccine has not been established in patients with HIV infection, MMR and varicella individual vaccines have been recommended in children with HIV infection who are asymptomatic and not immunosuppressed (CDC immunologic category 1). Defer vaccination in patients with active untreated tuberculosis. Avoid use of salicylates for 6 weeks following vaccination; varicella may increase the risk of Reye's syndrome. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Products may contain albumin. Products may contain gelatin or neomycin; use is contraindicated in patients with a history of anaphylactic/anaphylactoid reaction to gelatin or neomycin; contact dermatitis due to neomycin is not a contraindication to the vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1582137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F1582121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1582122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Do not administer to pregnant females and pregnancy should be avoided for 3 months (per manufacturer labeling) following vaccination. The ACIP recommends that pregnancy should be avoided for 1 month following vaccination with any of the individual components of this vaccine. Refer to individual monographs. A pregnancy registry has been established for pregnant women exposed to varicella virus vaccine (800-986-8999). Refer to the Varicella Virus Vaccine monograph and the Measles, Mumps, and Rubella Virus Vaccine monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7775583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rash, fever; observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to re-establish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2886925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A live, attenuated virus; offers active immunity to disease caused by the measles, mumps, rubella, and varicella-zoster virus.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2886930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/20/14657?source=see_link\">",
"      see \"Measles, mumps, rubella, and varicella virus vaccine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Soreness or swelling may occur at the site of injection; fever, mild rash, swelling in the glands of the cheeks or neck, and temporary pain or stiffness in the joints may occur. Some effects may not occur until 1-2 weeks after the injection. Notify your healthcare provider immediately if these effects continue or are severe, or for a high fever, seizures, or allergic reaction (respiratory difficulty, hives, weakness, dizziness, fast heartbeat) occurs. Not to be given during pregnancy; do not get pregnant for 28 days after getting the vaccine.  Do not use aspirin or aspirin-containing products for 6 weeks following vaccination.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10192940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     MMR and MMRV vaccines are both associated with febrile seizures which may occur during the first 2 weeks following vaccination. Based on preliminary information, fever &ge;102&deg;F occurs more often with MMRV (21.5%) compared to separate MMR and varicella vaccines (14.9%) in children 12-23 months of age. Measles-like rash also occurs more often with MMRV (3%) than with separate MMR and varicella vaccines (2.1%) in this age group. Most cases resolve spontaneously. The risk of febrile seizures may be increased twofold in children receiving MMRV at age 12-23 months in comparison to separate MMR and varicella vaccines (risk is highest 5-12 days after first dose). This is not observed in older children (&ge;47 months of age). Immunization with either MMRV or separate MMR and varicella vaccines offers equivalent immunity with the first dose. Using the combination vaccine provides the child with one less injection. Parents and/or caregivers should be provided with information related to the benefits and risks of both options. The ACIP prefers administration of separate MMR and varicella vaccines as the first dose in this age group unless the parent or caregiver expresses preference for the MMRV combination. Children with a personal or family history of seizures should be vaccinated with separate MMR and varicella vaccines, as opposed to the MMRV combination vaccine (CDC, 2010). Results from a larger study confirm that children who were 12-23 months of age when receiving their first dose of MMRV vaccine were at an increased risk of fevers and seizures within 7-10 days after vaccination. Healthcare visits for fever and seizures were associated with both MMRV and separate MMR and varicella vaccines; however, the relative risk for seizures following vaccination was most significant with the MMRV vaccine. Seizures occurred most often 8-10 days following MMRV vaccination (RR 7.6, p &lt;0.0001), 7-10 days following separate MMR and varicella vaccination (RR 4.0, p&lt;0.0001), and 7-11 days following MMR vaccination (RR 3.7, p&lt; 0.0001); no peak in seizures was observed following varicella vaccine alone. Healthcare visits due to fever also clustered between 7-10 days after vaccination with any measles-containing vaccine (MMRV RR 6.1, MMR and varicella RR 4.4, MMR RR 4.3). Following a chart review for verification of seizure type, the rate of febrile seizures was 87% following both MMRV and separate MMR and varicella vaccine administration (Klein, 2010).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/23/14710/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/23/14710/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination &minus; United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/23/14710/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Use of Combination Measles, Mumps, Rubella, and Varicella Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-3):1-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/23/14710/abstract-text/20448530/pubmed\" id=\"20448530\" target=\"_blank\">",
"        20448530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein NP, Fireman B, Yih WK, et al, \"Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(1):e1-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/23/14710/abstract-text/20587679/pubmed\" id=\"20587679\" target=\"_blank\">",
"        20587679",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/23/14710/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nolan T, Bernstein DI, Block SL, et al, \"Safety and Immunogenicity of Concurrent Administration of Live Attenuated Influenza Vaccine With Measles-Mumps-Rubella and Varicella Vaccines to Infants 12 to 15 Months of Age,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(3):508-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/23/14710/abstract-text/18310199/pubmed\" id=\"18310199\" target=\"_blank\">",
"        18310199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/23/14710/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12990 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14710=[""].join("\n");
var outline_f14_23_14710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1433435\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10407944\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886917\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886926\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1582151\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1433437\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886927\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886924\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886918\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1582134\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886920\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3871904\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886921\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299649\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1582137\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1582121\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1582122\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7775583\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886925\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886930\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10192940\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12990\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12990|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29334?source=related_link\">",
"      Measles, mumps, rubella, and varicella virus vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/20/14657?source=related_link\">",
"      Measles, mumps, rubella, and varicella virus vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_23_14711="Evaluation of foot and ankle pain in the young athlete";
var content_f14_23_14711=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of foot and ankle pain in the young athlete",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/23/14711/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14711/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14711/contributors\">",
"     Christopher R Powers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/23/14711/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14711/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14711/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/23/14711/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14711/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/23/14711/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of all musculoskeletal complaints are related to the foot and ankle, which is not surprising if one considers the functions of the foot:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It provides a stable base on which the body can stand.",
"     </li>",
"     <li>",
"      It acts as a rigid lever to propel the body forward during walking.",
"     </li>",
"     <li>",
"      It provides shock absorption for the force generated during walking and running (approximately two to six times an individual's body weight).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis and treatment of foot and ankle injuries in the young athlete require knowledge of anatomy, gait, and biomechanics. These topics and the general evaluation of foot and ankle injuries in the young athlete are reviewed here.",
"   </p>",
"   <p>",
"    Detailed discussions of specific injuries, including fractures of the foot and ankle, are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link\">",
"       \"Clinical features and management of ankle pain in the young athlete\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=see_link\">",
"       \"Clinical features and management of heel pain in the young athlete\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24345?source=see_link\">",
"       \"Ankle fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35079?source=see_link\">",
"       \"Foot fractures (other than metatarsal or phalangeal) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14903?source=see_link\">",
"       \"Metatarsal and toe fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The foot can be divided into three functional parts: the hindfoot, midfoot, and forefoot [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14711/abstract/1\">",
"     1",
"    </a>",
"    ]. The hindfoot, which consists of the talus and the calcaneus, connects to the midfoot at the midtarsal (Chopart) joint. The midfoot contains the navicular, the cuboid, and the three cuneiform bones; it connects to the forefoot at the Lisfranc joint. The forefoot includes everything distal to the Lisfranc joint, including the metatarsals, sesamoids, and phalanges (",
"    <a class=\"graphic graphic_picture graphicRef52540 \" href=\"UTD.htm?35/33/36375\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The foot has 28 bones, including 14 phalanges, seven tarsal bones (talus, calcaneus, cuboid, navicular, and three cuneiforms), five metatarsals, and two sesamoids. The bones that are clinically significant can be organized according to their dynamic articulations (",
"    <a class=\"graphic graphic_picture graphicRef52540 \" href=\"UTD.htm?35/33/36375\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14711/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;The foot has four joints: the ankle (mortise), subtalar (talocalcaneal), midtarsal (Chopart), and midfoot (Lisfranc) (",
"    <a class=\"graphic graphic_picture graphicRef52540 \" href=\"UTD.htm?35/33/36375\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The distal tibia and fibula form the roof of the ankle joint. The dome of the talus fits snugly into the tibia and fibula. The primary plane of movement at the ankle joint is",
"    <span class=\"nowrap\">",
"     plantarflexion/dorsiflexion.",
"    </span>",
"   </p>",
"   <p>",
"    The subtalar joint is composed of the anterior, middle, and posterior articulations between the talus and the calcaneus. They are separated laterally by the sinus tarsi and medially by the tarsal canal. The subtalar joint is responsible for hindfoot",
"    <span class=\"nowrap\">",
"     inversion/eversion",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     abduction/adduction.",
"    </span>",
"   </p>",
"   <p>",
"    The talonavicular and calcaneocuboid articulations comprise the midtarsal joint and demarcate the hindfoot from the midfoot. They are responsible for \"unlocking\" the midfoot during subtalar pronation, allowing the foot to absorb more shock, and for \"locking\" the midfoot during subtalar supination, allowing the foot to become a rigid lever for propulsion.",
"   </p>",
"   <p>",
"    The midfoot or Lisfranc joint is the articulation between the three cuneiforms and the proximal second metatarsal. It provides rigid stability to optimize efficiency through the medial column of the foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ligaments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ankle has three main groups of ligaments (",
"    <a class=\"graphic graphic_figure graphicRef72462 graphicRef51952 \" href=\"UTD.htm?6/23/6518\">",
"     figure 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14711/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lateral ligament complex&ndash; This complex has three components:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The anterior talofibular ligament (ATFL) connects the talus and distal fibula anteriorly.",
"     </li>",
"     <li>",
"      The calcaneofibular ligament (CFL) connects the calcaneus and distal fibula directly inferior to the lateral malleolus.",
"     </li>",
"     <li>",
"      The posterior talofibular ligament (PTFL) connects the talus and fibula posteriorly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medial ligament complex &ndash; The deltoid ligament, located on the medial side of the ankle, is a broad band of connective tissue that has four separate divisions that connect the distal tibia with the talus, calcaneus, and the navicular bones.",
"     </li>",
"     <li>",
"      Tibiofibular ligament complex &ndash; The tibiofibular complex consists of the anterior and posterior tibiofibular and the interosseous membrane and ligament. This complex is responsible for maintaining the relationship between the distal tibia and fibular and preventing them from splaying apart with a cephalad force from the talus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The plantar fascia is the primary aponeurosis that originates on the plantar aspect of the calcaneus and fans out to attach to the base of each of the five metatarsal heads. It acts to reinforce the medial arch during the propulsion phase of gait. Its windlass effect on the medial longitudinal arch is important to the biomechanics of the foot during the toe-off phase. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Gait cycle'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscles of the foot and ankle originate above the ankle (extrinsics) and within the foot (intrinsics) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14711/abstract/1\">",
"     1",
"    </a>",
"    ]. The extrinsic muscles permit the larger force-generating muscles to be located away from the foot and to avoid interference with the intrinsic structure of the foot (",
"    <a class=\"graphic graphic_figure graphicRef54716 \" href=\"UTD.htm?31/28/32196\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71142 \" href=\"UTD.htm?7/35/7728\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The anterior or extensor compartment of the leg includes the following muscles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tibialis anterior originates on the proximal anterior tibia and courses distally in its synovial sheath beneath the extensor retinaculum to insert on both the medial cuneiform and the medial base of the first metatarsal. It dorsiflexes and inverts the foot.",
"     </li>",
"     <li>",
"      The extensor hallucis longus (EHL) inserts on the dorsal aspect of the base of the distal phalanx of the great toe. It extends the great toe and dorsiflexes the foot.",
"     </li>",
"     <li>",
"      The extensor digitorum longus (EDL) has a distal attachment on the middle and distal phalanges of the lateral four digits and acts to extend these lateral four digits and dorsiflex the foot.",
"     </li>",
"     <li>",
"      The peroneus tertius inserts on the base of the fifth metatarsal bone and acts in a minor role in dorsiflexion and eversion of the foot.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lateral compartment of the leg contains the peroneus longus and peroneus brevis. The peroneus longus inserts on the base of the first metatarsal bone and medial cuneiform bone and acts to evert the foot and weakly plantarflex it. The peroneus brevis inserts on the base of the fifth metatarsal and has the same action as does the peroneus longus.",
"   </p>",
"   <p>",
"    The superficial posterior compartment of the leg contains the triceps surae (the gastrocnemius and soleus complex), which insert via the Achilles tendon into the posterior surface of the calcaneus. They are the force generators that plantarflex the foot and weakly evert the heel.",
"   </p>",
"   <p>",
"    The deep posterior compartment of the leg contains the tibialis posterior (TP), flexor digitorum longus (FDL), and flexor hallucis longus (FHL) muscles.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The TP passes under the medial malleolus to insert on the tuberosity of the navicular bone, along with additional insertion points on the cuboid, and the base of the second, third, and fourth metatarsal bones. It functions to plantarflex and invert the foot.",
"     </li>",
"     <li>",
"      The FDL inserts on the base of the distal phalanges of the lateral four digits and this flexes these four digits, plantarflexes the foot, and supports the longitudinal arch of the foot.",
"     </li>",
"     <li>",
"      The FHL inserts on the base of the distal phalanx of the great toe and is responsible for flexing the great toe at all joints, plantarflexing the foot, and supporting the longitudinal arch of the foot.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dorsalis pedis artery is a continuation of the anterior tibial artery that crosses the anterior joint line of the ankle just deep to the extensor hallucis longus. As the artery proceeds down the long axis of the foot to the proximal first intermetatarsal space, it divides into a deep plantar artery and an arcuate artery that sends off branches to each of the toes.",
"   </p>",
"   <p>",
"    The arteries in the sole of the foot are derived from the posterior tibial artery and form the medial and lateral plantar arteries. The lateral plantar branch sends off branches through the plantar arterial arch, which anastomoses with the deep plantar artery for the dorsalis pedis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common peroneal and tibial nerve are the two major divisions of the sciatic nerve that branch just above the knee. The common peroneal nerve is the nerve that is injured most often in the lower limb. Severance of this nerve causes a foot drop because of the paralysis of the dorsiflexion and eversion muscles of the foot.",
"   </p>",
"   <p>",
"    The common peroneal nerve splits into a superficial and deep branches just distal to the fibular head. The superficial branch provides sensation to the lateral aspect of the dorsum of the foot and innervates the peroneals (hindfoot evertors). The deep branch provides sensation to the interdigital space between the first and second toe and is responsible for dorsiflexing the ankle and toes. The tibial nerve proceeds posterior to the medial malleolus and becomes the medial and lateral plantar nerves. The tibial and peroneal nerves give off branches that form the sural nerve, which supplies sensation to the lateral aspect of the ankle and foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     BIOMECHANICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the structural divisions discussed above, the foot can be divided into two functional columns: medial and lateral [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14711/abstract/2\">",
"     2",
"    </a>",
"    ]. The medial column, consisting of the calcaneus, talus, navicular, medial cuneiforms, and medial three toes, forms the medial longitudinal arch and is the main axis for weightbearing and propulsion. The lateral column, consisting of the calcaneus, cuboid, and lateral two toes, forms the lateral longitudinal arch and is the main axis for proprioception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gait cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of the gait cycle is helpful in understanding the complex movements of the foot that occur during walking and running. The subtalar movement controls the locking and unlocking of the midtarsal joints and determines the actions of the forefoot. These coupled motions of the foot allow it to perform its various functions. Pronation, which provides maximum shock absorption, occurs when the tibia internally rotates, the talus adducts and plantarflexes, and the calcaneus everts. Supination, which converts the foot into a rigid lever, occurs when the tibia externally rotates, the talus abducts and dorsiflexes, and the calcaneus inverts.",
"   </p>",
"   <p>",
"    The gait cycle has four phases (",
"    <a class=\"graphic graphic_figure graphicRef53103 \" href=\"UTD.htm?6/5/6224\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heel-strike to foot-flat (contact)",
"     </li>",
"     <li>",
"      Foot-flat to heel-off (mid-stance)",
"     </li>",
"     <li>",
"      Heel-off to toe-off (propulsion)",
"     </li>",
"     <li>",
"      Toe-off to heel-strike (swing)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Contact",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the contact phase, the lateral calcaneus strikes the ground. At the point of impact, the tibia internally rotates, causing the calcaneus to evert and talus to drop and adduct to unlock the midtarsal joints and provide maximum shock absorption. The foot is lowered eccentrically to the ground by the extensor digitorum longus and tibialis anterior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mid-stance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the midstance phase, the cycle progresses from the flat-foot to the heel-off. As the rearfoot fully pronates, the metatarsals hit the ground to bring the foot flat on the ground. The body's center of gravity passes from behind to over the foot. During this phase, the subtalar joint resupinates (calcaneus everts and talus abducts) and locks the midtarsal joints, transforming the foot from a shock absorber to a rigid lever. The posterior tibialis is an important restraint to overpronation and is an active foot supinator. As the body passes over the mid-foot, it places the ankle in maximal dorsiflexion, putting a maximal preload on the gastrocnemius-soleus complex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Propulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the propulsion phase, the heel-lift progresses to toe-off. As the heel rises, the body continues forward over the metatarsals and begins to pull the heel off the ground. The extension of the metatarsophalangeal (MTP) joints, especially the first MTP joint, result in the windlass effect of the plantar fascia that elevates the arch and further assists in the supination of the foot. The foot is now a rigid lever and is used to propel the body forward by maximal contraction of the gastrocnemius-soleus and hamstrings. At toe-off, the line of progression usually passes between the first and second metatarsal that are in maximal extension. This phase concludes with the body weight moving over the great toe at toe-off.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Swing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The swing phase is the last phase of the gait cycle. The foot dorsiflexes to keep the toes from hitting the ground and supinates to position the foot for the lateral calcaneus to make contact at heel strike, and the cycle repeats itself (",
"    <a class=\"graphic graphic_figure graphicRef53103 \" href=\"UTD.htm?6/5/6224\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The problems relating to the foot and ankle can be divided into acute and chronic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Acute injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute injuries usually have a definitive mechanism of injury and often require immediate evaluation and therapy. Important questions to ask in the history include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14711/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What was the mechanism of the injury?",
"     </li>",
"     <li>",
"      Was there a mechanical sensation, such as a popping or cracking, at the time of the injury?",
"     </li>",
"     <li>",
"      Has there been a persistent feeling of instability in the foot or ankle since the injury occurred?",
"     </li>",
"     <li>",
"      What type of activity led to the injury?",
"     </li>",
"     <li>",
"      What is the location, radiation, intensity, and duration of pain?",
"     </li>",
"     <li>",
"      What aggravates the pain and what factors alleviate the pain?",
"     </li>",
"     <li>",
"      Does the patient have numbness or tingling in the foot and ankle region?",
"     </li>",
"     <li>",
"      Does the patient have weakness that may or may not be related to the pain?",
"     </li>",
"     <li>",
"      Can the patient bear weight? Can he or she ambulate?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Chronic problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic foot and ankle problems require the examiner to establish an accurate chronology and to identify specific activities that cause the pain. For chronic problems, important questions include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14711/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What activity seems to worsen the problem?",
"     </li>",
"     <li>",
"      How often and for how long does the patient engage in the activity?",
"     </li>",
"     <li>",
"      Has there been a recent increase in the amount or duration of activity?",
"     </li>",
"     <li>",
"      Is pain present during or after activity, or both?",
"     </li>",
"     <li>",
"      Is pain present when the patient takes his or her first steps in the morning?",
"     </li>",
"     <li>",
"      Is there a problem with activities of daily living, such as ascending or descending stairs?",
"     </li>",
"     <li>",
"      Is the problem only exacerbated by sports?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Training",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above questions, if the patient is an athlete, he or she should be questioned about training. As an example, if the patient is a runner, the examiner should ask about weekly mileage, type of running surface, typical stretching routine, shoe type, and the use of orthotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Past history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Past medical history and a related review of systems also should be assessed. For chronic illnesses, ask what medications, physical therapy, home rehabilitation, or shoe or activity modifications have been tried. Considering systemic medical illnesses or conditions that may affect the foot and ankle is important. As an example, nontraumatic acute onset of pain with swelling and erythema in the first metatarsophalangeal joint can be caused by gout. Rheumatologic conditions may have early morning stiffness, involvement of multiple joints, back",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hip pain and stiffness, skin rash, or positive family history. The pertinent history related to specific injuries is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link\">",
"     \"Clinical features and management of ankle pain in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=see_link\">",
"     \"Clinical features and management of heel pain in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of the young athlete with foot or ankle complaints includes inspection, palpation, range of motion, and provocative and functional testing.",
"   </p>",
"   <p>",
"    Manipulation of the extremity should be minimized and neurovascular status promptly evaluated if obvious deformity is present. Breaks in the skin may indicate an open fracture, and the need for antibiotic coverage must be assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14711/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspection of the foot and ankle should occur with the patient in various positions: seated, prone or kneeling on a chair, standing in various poses, and walking.",
"   </p>",
"   <p>",
"    With the patient seated (non-weightbearing), the examiner should examine the foot and the ankle for swelling, ecchymosis, erythema, deformity, and dermatologic findings (eg, rashes, warts, ulcers, calluses, blisters, corns, and nail abnormalities).",
"   </p>",
"   <p>",
"    With the patient prone or kneeling on a chair and the foot in the neutral position, the orientation (eg, varus or valgus) of the forefoot should be noted.",
"   </p>",
"   <p>",
"    With the patient standing normally,",
"    <span class=\"nowrap\">",
"     varus/valgus",
"    </span>",
"    or torsional deformities of the tibia, hallux, and rearfoot should be noted. The position of the forefoot (abduction versus adduction) should be noted. The toes should be inspected for deformities (eg, claw, mallet, hammer). The patient should then be asked to stand with the feet three to four inches apart and to march in place for three to four steps. Once the patient has assumed the relaxed natural position, the presence of pes planus (flat foot) or cavus (high-arched foot) should be noted.",
"   </p>",
"   <p>",
"    Asking the patient to stand on his or her toes permits evaluation of muscle wasting in the gastrocnemius-soleus complex, function of the posterior tibialis muscle, and dynamic function of the arch. These observations are best made while standing behind the patient. As the patient rises on his or her toes, inversion of the heel indicates normal function of the posterior tibialis. In addition, the medial longitudinal arch should increase in height. Lack of elevation of the arch indicates a static pes planus that could be caused by tarsal coalition or injury to the subtalar joint. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link\">",
"     \"Clinical features and management of ankle pain in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=see_link\">",
"     \"Clinical features and management of heel pain in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient should be asked to walk, and several gait cycles should be observed (",
"    <a class=\"graphic graphic_figure graphicRef53103 \" href=\"UTD.htm?6/5/6224\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the foot and ankle should include palpation of the bony landmarks, including the ligaments (",
"    <a class=\"graphic graphic_figure graphicRef72462 graphicRef51952 \" href=\"UTD.htm?6/23/6518\">",
"     figure 1A-B",
"    </a>",
"    ) and tendons, and the dorsalis pedis and posterior tibialis pulses. In addition, sensory examination of the nerves of the foot and ankle should be performed.",
"   </p>",
"   <p>",
"    Heel pain may be caused by deep venous thrombosis of the gastrosoleus. Physical examination may reveal a palpable cord (reflecting a thrombosed vein), ipsilateral edema, warmth,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    superficial venous dilation. However, because the symptoms and findings are nonspecific, testing is usually indicated to confirm or exclude the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\", section on 'Clinical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the foot and ankle should include passive and active range of motion for the following actions: plantarflexion, dorsiflexion, inversion, and eversion of the foot; flexion and extension of the toes, particularly the great toe. Plantarflexion and dorsiflexion should be tested with the knee flexed and then extended. Dorsiflexion at the ankle that is limited only when the knee is extended indicates contracture of the gastrocnemius muscle, which originates at the distal femur [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14711/abstract/6\">",
"     6",
"    </a>",
"    ]. Testing these actions against resistance evaluates motor function and strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Provocative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provocative testing of the foot and ankle includes various maneuvers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior drawer test evaluates stability of the ATFL. The examiner uses one hand to cup the heel of the affected foot and the opposite hand to stabilize the anterior portion of the distal tibia and fibula. The examiner then uses the hand on the heel to pull the foot anteriorly; the amount of anterior translation of the talus on the mortise should be noted. The test is abnormal when 3 to 5 mm more translation is present compared with the opposite side.",
"     </li>",
"     <li>",
"      The inversion stress test evaluates the stability of the lateral ligament complex (the ATFL and the CFL). The examiner uses one hand to cup the heel of the affected foot and the opposite hand to stabilize the anterior portion of the distal tibia and fibula. The ATFL is evaluated by maximally plantarflexing the ankle and then inverting the rearfoot; laxity and pain should be noted. The CFL is evaluated by maximally dorsiflexing the foot and then inverting the rearfoot. The test is considered abnormal when 10 to 15 degrees more inversion is present, compared with the opposite side.",
"     </li>",
"     <li>",
"      Test for Morton's neuroma &ndash; The examiner grasps consecutive metatarsal heads and compresses them together. If a click, as well as reproduction of the patient&rsquo;s pain, occurs, a Morton's neuroma should be suspected (",
"      <a class=\"graphic graphic_figure graphicRef65666 \" href=\"UTD.htm?0/3/56\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Thompson test for complete Achilles rupture &ndash; With patient lying prone and the foot hanging off the table, the gastrocnemius is squeezed. If the foot does not plantarflex, rupture of the Achilles tendon must be considered (",
"      <a class=\"graphic graphic_picture graphicRef74412 \" href=\"UTD.htm?36/62/37860\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Peroneal subluxation test &ndash; With the patient seated, the patient actively dorsiflexes and everts the foot against resistance; the examiner simultaneously palpates the peroneal tendon posterior to the distal fibula. Pain, clicking, or sensation of instability may indicate subluxation of the peroneal tendon.",
"     </li>",
"     <li>",
"      High-ankle sprain tests include the syndesmosis squeeze, dorsiflexion, and external rotation tests. All tests are performed with the patient seated, and if positive, will result in pain over the tibiofibular ligaments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Squeeze test &ndash; The examiner will place their hands opposite each other around the middle third of the patient&rsquo;s lower leg in the squeeze test. Pain will be provoked when the tibia is directed posteriorly and the fibular anteriorly.",
"     </li>",
"     <li>",
"      Dorsiflexion test &ndash; The examiner passively dorsiflexes the ankle, which will provoke the pain.",
"     </li>",
"     <li>",
"      External rotation test &ndash; The examiner passively external rotates the foot while stabilizing the lower leg, which will provoke the pain. This is repeated with a compressive force on the malleoli that decreases the patient&rsquo;s pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Functional",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional testing of the foot and ankle involves asking the patient to walk with a normal gait, on his or her toes, and on his or her heels. The patient should also be asked to run a short distance and to hop five times on each foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Radiologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiologic evaluation of the young athlete with foot or ankle pain depends upon the location of the pain and the conditions being considered in the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef68769 graphicRef82706 graphicRef58865 \" href=\"UTD.htm?35/22/36206\">",
"     table 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs (anteroposterior, lateral, and mortise views of the ankle) should be obtained in patients who have history and physical findings suggestive of distal fibular or malleolar fracture. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36376?source=see_link\">",
"     \"Overview of ankle fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24345?source=see_link\">",
"     \"Ankle fractures in children\"",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    The Ottawa ankle rules (OAR) (",
"    <a class=\"graphic graphic_figure graphicRef69818 \" href=\"UTD.htm?32/53/33618\">",
"     figure 5",
"    </a>",
"    ), designed to predict the need for radiographs in adults with acute ankle trauma, suggest that radiographs need only be obtained if there is pain near the malleoli and either:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inability to bear weight (four steps) immediately after the injury and at the time of evaluation OR",
"     </li>",
"     <li>",
"      Bone tenderness at the posterior edge or tip of either malleolus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The OAR are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34296?source=see_link&amp;anchor=H19#H19\">",
"     \"Ankle sprain\", section on 'Ottawa ankle rules'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The OAR should not be used routinely in children under 16 years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24345?source=see_link&amp;anchor=H12#H12\">",
"     \"Ankle fractures in children\", section on 'Ottawa Ankle Rules'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Other injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features and recommended radiologic evaluation of conditions other than fractures that cause ankle, heel, and foot pain in young athletes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link\">",
"     \"Clinical features and management of ankle pain in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=see_link\">",
"     \"Clinical features and management of heel pain in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34296?source=see_link\">",
"     \"Ankle sprain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a general rule, when plain radiographs of the ankle are obtained, an anteroposterior, lateral, and mortise view should be obtained; additional views (eg, in plantar of dorsiflexion) are sometimes necessary. Plain radiographs may demonstrate abnormalities in patients with osteochondritis dissecans, stress fractures, sinus tarsi syndrome, and accessory ossicles (",
"    <a class=\"graphic graphic_table graphicRef68769 graphicRef82706 graphicRef58865 \" href=\"UTD.htm?35/22/36206\">",
"     table 1A-C",
"    </a>",
"    ). Plain radiographs also are often obtained to exclude bony injuries in patients in whom tendon injuries are being considered. However, MRI is a better modality for demonstrating these injuries.",
"   </p>",
"   <p>",
"    Plain radiographs of the feet (anteroposterior, lateral, and oblique views) may be helpful in the diagnosis of os peroneum and os tibiale externum, and tibialis posterior tendon dysfunction (",
"    <a class=\"graphic graphic_table graphicRef68769 graphicRef82706 graphicRef58865 \" href=\"UTD.htm?35/22/36206\">",
"     table 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Radiographs are not usually necessary in the evaluation of flexor digitorum longus injuries, tibialis anterior injuries, calcaneal apophysitis, plantar fasciitis, or flexible flat feet (unless patients have associated pain, restricted mobility, or are being considered for surgery).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8058557\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foot and ankle pain is a common complaint in the young athlete. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation includes careful history and a complete physical examination, including provocative testing of the ligaments and tendons of the foot and ankle, assessment of range of motion, and observation of gait. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Young athletes with an acute injury and an evaluation that suggests a possible fracture warrant radiographic evaluation. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tables provide the mechanism of injury, location of pain, and radiologic findings for specific conditions, other than fractures, that cause foot and ankle pain in the young athlete (",
"      <a class=\"graphic graphic_table graphicRef68769 graphicRef82706 graphicRef58865 \" href=\"UTD.htm?35/22/36206\">",
"       table 1A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Other injuries'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Moore, KL. Clinically Oriented Anatomy of the Foot and Ankle, 3rd, Williams &amp; Wilkins, Baltimore 1992.",
"    </li>",
"    <li>",
"     Noordin, M, Frankel, V. Basic Biomechanics of the Musculoskeletal System, 2nd, Lea and Febiger, Philadelphia 1989.",
"    </li>",
"    <li>",
"     Reid, DC. Sports Injury Assessment and Rehabilitation, Churchill Livingstone, New York 1992.",
"    </li>",
"    <li>",
"     Techdijan, MO. Clinical Pediatric Orthopedics, Appleton and Lange, Stamford 1997.",
"    </li>",
"    <li>",
"     Anderson, AC. Injury - Ankle. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludgwig, S, Henretig, FM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.363.",
"    </li>",
"    <li>",
"     Staheli, LT. Foot. In: Fundamentals of Pediatric Orthopedics, 2nd, Lippincott-Raven, Philadelphia 1998. p.41.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6525 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.150-9E46D5F071-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14711=[""].join("\n");
var outline_f14_23_14711=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8058557\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Joints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nerves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      BIOMECHANICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gait cycle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Contact",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mid-stance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Propulsion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Swing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Acute injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Chronic problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Training",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Past history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Inspection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Palpation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Range of motion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Provocative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Functional",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Radiologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Other injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8058557\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6525\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6525|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/9/159\" title=\"figure 1A\">",
"      Lateral ankle ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/57/35728\" title=\"figure 1B\">",
"      Medial ankle ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/28/32196\" title=\"figure 2\">",
"      Foreleg and foot muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/5/6224\" title=\"figure 3\">",
"      Gait cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/3/56\" title=\"figure 4\">",
"      Morton neuroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/53/33618\" title=\"figure 5\">",
"      Ottawa ankle rules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6525|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/33/36375\" title=\"picture 1\">",
"      Bones of the foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/35/7728\" title=\"picture 2\">",
"      Surface contour leg muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/62/37860\" title=\"picture 3\">",
"      Thompson squeeze test for Achilles tendon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6525|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/50/34604\" title=\"table 1A\">",
"      DDx Foot ankle pain athlete A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/38/17004\" title=\"table 1B\">",
"      DDx Foot ankle pain athlete B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/59/14269\" title=\"table 1C\">",
"      DDx Foot ankle pain athlete C",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24345?source=related_link\">",
"      Ankle fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34296?source=related_link\">",
"      Ankle sprain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=related_link\">",
"      Clinical features and management of ankle pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=related_link\">",
"      Clinical features and management of heel pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35079?source=related_link\">",
"      Foot fractures (other than metatarsal or phalangeal) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14903?source=related_link\">",
"      Metatarsal and toe fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36376?source=related_link\">",
"      Overview of ankle fractures in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_23_14712="Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond";
var content_f14_23_14712=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/23/14712/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14712/contributors\">",
"     Ilseung Cho, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14712/contributors\">",
"     Irphan Gaslightwala, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14712/contributors\">",
"     Jonathan Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/23/14712/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14712/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/23/14712/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14712/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/23/14712/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1975, two Japanese groups developed a method by which to deploy a hemostatic metal clip through a flexible endoscope for the purpose of hemostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The early clips were cumbersome and difficult to use, complicated by frequent misfire rates and technical difficulties in positioning the clip during endoscopy. However, their use spread rapidly through Japan initially and then in Europe. More recently endoscopic clipping technology has also gained greater acceptance in the United States.",
"   </p>",
"   <p>",
"    Endoscopic clips are used widely not only for the treatment of gastrointestinal bleeding but also for a variety of other gastrointestinal problems. In this review, we will describe the various clips currently available along with basic principles of clip application. The practical aspects of particular applications and the evidence supporting their role will also be presented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AVAILABLE CLIPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most recent iterations of endoclips are a marked improvement over earlier models. They are available in multiple sizes and some can be rotated or reopened while being deployed through the endoscope. Four companies produce disposable endoclips for use in the United States market.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Olympus USA, Corp. produces the QuickClip2, which is a rotatable clip device (",
"      <a class=\"graphic graphic_picture graphicRef52806 \" href=\"UTD.htm?27/22/28001\">",
"       picture 1",
"      </a>",
"      ). These devices are produced in two sizes, 8 mm or 12 mm in width when opened and 165 cm to 230 cm in length, allowing deployment through a colonoscope.",
"     </li>",
"     <li>",
"      Boston Scientific, Inc. produces the Resolution Clip, which cannot be rotated but can be reopened after closure if repositioning is required (",
"      <a class=\"graphic graphic_picture graphicRef67534 \" href=\"UTD.htm?14/61/15314\">",
"       picture 2",
"      </a>",
"      ). The Resolution Clip has an opening width of 11 mm and is available in lengths of 165 cm and 235 cm.",
"     </li>",
"     <li>",
"      Cook Medical produces the TriClip, a three-pronged endoclip whose efficacy has not yet been as rigorously evaluated as the traditionally shaped clipping devices (",
"      <a class=\"graphic graphic_picture graphicRef68200 \" href=\"UTD.htm?25/34/26146\">",
"       picture 3",
"      </a>",
"      ). The TriClip opens to a width of 12 mm and is 205 cm long. Preliminary experience has not detected obvious advantages of this configuration [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another clip from Cook Medical that is not yet commercially available is the Instinct Endoscopic Hemoclip. It opens to a width of 16 mm and allows for 360 degree bidirectional rotation. In addition, the jaws can be reopened to reposition the clip.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All clips have sizes that fit through the standard 2.8 mm biopsy channel so they can be used with both diagnostic and therapeutic caliber endoscopes. There are no endoclips that are long enough to be deployed through a standard push enteroscope longer than 180 cm. The specifications of clip devices commercially available in North America are summarized in table 1 (",
"    <a class=\"graphic graphic_table graphicRef57403 \" href=\"UTD.htm?29/8/29835\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Reusable clip deployment devices from Olympus are still available but used infrequently in the United States mainly because they are difficult to clean and sterilize. In Europe the reusable deployment devices (EZ Clip) are used more commonly; they are available in six different models and sizes of hemoclips.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF HEMOSTASIS, TISSUE APPOSITION, AND RETENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoclips are steel, mechanical devices that cause hemostasis by grasping vessels or surrounding tissue. Although they cause tissue compression, they do not cause inflammation or acute tissue injury such as occurs with sclerosants or thermal coagulation.",
"   </p>",
"   <p>",
"    Control of bleeding is generally successful when Endoclips are used for bleeding acute ulcers, or lesions such as Mallory-Weiss tears. By contrast, control of bleeding is less successful for lesions that are fibrotic (such as chronic ulcers), especially when using smaller endoclips or those that cannot be rotated. A failure rate as high as 20 percent has been described with chronic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apposition of the sides of lesions such as ulcers, tears, or acute perforations is a fundamental surgical principle for tissue repair and healing that is often possible with endoscopic clips. Repair and healing are possible if the endoclip can be placed across the lesion into soft, normal-appearing tissue. There is some evidence that ulcer healing is accelerated when the sides are apposed and that ulcers heal more rapidly with endoclips compared with thermally-treated ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retention rates (the duration that endoclips remain in position until sloughing into the lumen) on ulcers vary remarkably. Studies in a porcine model suggest that the Resolution device may remain attached for a longer duration (four to five weeks) than the other commercially available devices [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/7\">",
"     7",
"    </a>",
"    ], but this observation has not been confirmed in humans. To be successful, endoclips must remain in place at least until collagen deposition occurs, which may take several weeks. Longer, rotatable, grasp and release hemoclips or clips with interlocking jaws appear to be the most promising for these indications. TriClip models have the lowest retention rate on acute or chronic ulcers (&lt;25 percent at one week), whereas the other hemoclips have &gt;50 percent retention after one week and may actually stay on longer than ulcer healing time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF APPLICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specifics of deploying the different brands of endoclips are different for each type. However, the general principles for effective deployment remain the same and many of the basic techniques are used for deployment regardless of the lesion being treated. Endoscopists and assistants should be trained in the specifics of several models.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For Olympus QuickClip models, the handle of the endoclip device is partially closed until the jaws are opened to their maximal opening. The endoclip is then pressed into the soft tissue and the handle of the clip device is fully closed, deploying the clip into the tissue.",
"     </li>",
"     <li>",
"      Boston Scientific Resolution clips are deployed in a similar method, although the jaws can be reopened after closing them on the lesion.",
"     </li>",
"     <li>",
"      The Cook TriClip deployment involves closing the handle to the desired force of clip grasp and then releasing the clip by opening the handle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Effective intervention requires good visualization of the lesion, whether it is an ulcer, a tear, or a perforation. Once the lesion is identified, the endoscope is stabilized with the target lesion in view. The endoclip is then passed through the suction channel of the endoscope and extended into the field of view. The endoclip is primed for firing and maneuvered into position. Some endoclip models can be rotated to improve positioning. Once the endoclip is positioned adequately, it is extended so that the jaws are across the target of interest and pressed into the adjacent tissue. The endoclip is then fired, causing the jaws to close and tightly appose the tissue. The Boston Scientific and Cook Medical Instinct Endoscopic Hemoclip jaws close on the target before deployment of the hemoclip. As a result, the jaws on these clips can be reopened and repositioned before deployment. Several endoclips may be required for complete intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BLEEDING PEPTIC ULCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before hemoclips, the mainstay of hemostasis was injection therapy or various thermal coagulation methods. More recently, at least nine randomized controlled trials have evaluated the efficacy of endoclips used alone or in combination with other methods. The majority used the standard sized Olympus endoclips (8 mm open) and were conducted outside of the United States. The comparator groups differed among the trials, trial quality was variable, and in many the sample size may have been too small to detect important differences.",
"   </p>",
"   <p>",
"    Despite these limitations, the data considered together suggest that Olympus hemoclips have similar efficacy as thermal coagulation methods [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/8\">",
"     8",
"    </a>",
"    ]. There are no randomized studies of newer hemoclips for emergency hemostasis, or comparisons of different types of hemoclips. Also, there are no comparisons of different sizes of hemoclips. More randomized studies by experienced and trained endoscopists will be needed to study the newer hemoclips, the grasp and release improvement, and whether larger size makes a difference for emergency hemostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summarizes the range of findings in the controlled trials. Two compared endoclips to thermal coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/4,9\">",
"     4,9",
"    </a>",
"    ], five to injection monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/10-14\">",
"     10-14",
"    </a>",
"    ], and two to combination therapy with injection and coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies comparing the endoclip to the heater probe have shown mixed results for initial control of bleeding and rebleeding rates [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/4,9\">",
"       4,9",
"      </a>",
"      ]. One report of 113 with major stigmata of ulcer hemorrhage found no difference in hemostasis, 30-day mortality, or need for emergency surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/9\">",
"       9",
"      </a>",
"      ]. Patients randomized to the endoclip group had significantly lower rebleeding rates (2 versus 21 percent). However, only 60 percent of active bleeders were successfully treated with the heater probe, a rate much lower than in previous reports.",
"     </li>",
"     <li>",
"      Another study of 80 patients found a higher rate of control of initial bleeding with the heater probe compared with the Olympus endoclip (100 versus 85 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/4\">",
"       4",
"      </a>",
"      ]. Rebleeding rates were not significantly different.",
"     </li>",
"     <li>",
"      Rebleeding rates were significantly lower with the endoclip compared with distilled water injections (10 versus 28 percent) in high-risk bleeding ulcers in a single study [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one trial, recurrent bleeding was decreased with endoclips compared with hypertonic saline-epinephrine injection (2 versus 15 percent) while combination therapy was no more effective than endoclip alone [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/11\">",
"       11",
"      </a>",
"      ]. By contrast, treatment failure was significantly higher in the endoclip group compared with epinephrine-polidocanol injection therapy (34 versus 6 percent) or a combination therapy arm (25 percent) in another study [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No significant differences in procedure duration, initial hemostasis, or rebleeding rates in a study of 47 patients comparing combination therapy with epinephrine injection plus monopolar electrocoagulation versus hemoclips [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/16\">",
"       16",
"      </a>",
"      ]. As a potential confounding issue, more than 22 percent of the hemoclip patients were pretreated with epinephrine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few studies have compared the various clips to one another. One such study, comparing the Hemoclip to the TriClip in patients with high-risk bleeding peptic ulcers, found superior hemostasis with the Hemoclip, particularly in sites that were difficult to approach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Special situations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some clinical settings in which endoclips may be preferred to other hemostatic methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They may be particularly useful in the treatment of ulcers in patients who are coagulopathic or require ongoing anticoagulation. In such patients, electrocoagulation will increase the size, depth, and healing time of treated lesions.",
"     </li>",
"     <li>",
"      Endoclips may have an advantage in the retreatment of lesions that rebleed after initial thermal hemostasis. Animal studies support reduced injury after ulcer hemostasis with hemoclips versus thermal coagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/6\">",
"       6",
"      </a>",
"      ]. Similarly, animal data suggest that healing may be accelerated with endoclips compared with thermal methods [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visualization of the target bleeding site is a prerequisite for accurate deployment. Ulcers on the lesser curvature, the posterior duodenum, or the cardia increase the difficulty of deployment and clip failure rates.",
"   </p>",
"   <p>",
"    For acute ulcers, the endoclip should be placed so that the jaws extend beyond the ulcer edge and are embedded into the surrounding soft tissue. Multiple endoclips may be required to close the walls of the lesion and achieve initial hemostasis (",
"    <a class=\"graphic graphic_picture graphicRef63669 \" href=\"UTD.htm?29/57/30612\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For chronic, fibrotic, or large ulcers, the endoclip should be placed on the major stigmata of hemorrhage, which is usually in the base of the lesion. Whether to use clips as a single modality therapy for active bleeding and visible vessels or in combination with epinephrine injection therapy warrants further study.",
"   </p>",
"   <p>",
"    Common errors to avoid:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deployment with clip tip too far away from the endoscope tip, leading to lack of control and precision",
"     </li>",
"     <li>",
"      Bumping of partly open clip against bowel lumen wall to displace previously placed clips (QuickClip2 or TriClip)",
"     </li>",
"     <li>",
"      Premature closure of the clip due to improper manipulation of the handle by the assistant (QuickClip2 or TriClip)",
"     </li>",
"     <li>",
"      Insufficient clips available to complete hemostasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MALLORY-WEISS TEARS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoclips have theoretical advantages compared to other hemostatic techniques in actively-bleeding Mallory-Weiss tears, although they have not been extensively compared. They do not cause significant tissue damage, permit rapid tissue apposition, and have a low risk of perforation.",
"   </p>",
"   <p>",
"    A few reports have described experience with endoclips with Mallory-Weiss tears [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Hemostasis was successful in all patients in a study of 26 patients with active bleeding or an adherent clot [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/19\">",
"     19",
"    </a>",
"    ]. In another study, Olympus endoclips were compared to epinephrine injection for hemostasis of an actively bleeding Mallory-Weiss tear in 35 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/20\">",
"     20",
"    </a>",
"    ]. There was no difference in rebleeding rates between the two groups. There have been no studies conducted comparing the efficacy of endoclips with electrocoagulation or combination therapy for the treatment of Mallory-Weiss tears. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43317?source=see_link\">",
"     \"Mallory-Weiss syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of endoclips in Mallory-Weiss tears is similar to treatment of acute ulcers or acute postpolypectomy bleeding (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Postpolypectomy bleeding'",
"    </a>",
"    below). Endoclips should be extended so that the opened jaws are perpendicular to the long axis of the tear and applied to close the sides of the tear and stop the active bleeding. Multiple endoclips may be required if the Mallory-Weiss tear is long or wide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIEULAFOY'S LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Dieulafoy's lesion is defined as active arterial bleeding or an adherent clot on an underlying vessel in the absence of an ulcer. At least two controlled trials suggested that endoclips can control acute bleeding and may reduce recurrent bleeding compared with injection therapy but there are no studies comparing it with thermal coagulation used alone or in combination with other methods [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Lesions in these studies were predominantly in the stomach and duodenum. Thermal coagulation has been considered the treatment of choice for hemostasis of bleeding Dieulafoy's lesions despite rebleeding rates as high as 50 percent. Other endoscopic methods have also been described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=see_link\">",
"     \"Uncommon causes of upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report found that endoscopic mechanical hemostasis was more effective for hemostasis of bleeding Dieulafoy's lesions than injection therapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/21\">",
"       21",
"      </a>",
"      ]. Although the study included band ligation in three patients in the mechanical hemostasis arm, the majority underwent endoclip therapy. Mechanical hemostasis was more effective in initial hemostasis (92 versus 75 percent), recurrent bleeding (8 versus 33 percent), and emergency surgery (0 versus 17 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second trial comparing endoclips to epinephrine injection found similar rates of initial hemostasis but dramatically lower rates of rebleeding in the endoclip arm (0 versus 35 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;For bleeding Dieulafoy's lesions, the bleeding artery must be identified precisely so that the endoclip can be accurately placed on the bleeding point. If the orientation of the bleeding vessel can be identified, the jaws of the endoclip should be placed perpendicularly across the vessel. It is important to grasp enough soft tissue around the bleeding vessel to mechanically compress it.",
"   </p>",
"   <p>",
"    The TriClip is well suited to perpendicular deployment, although the longer Resolution Clip may allow for more tamponade with soft tissue and longer retention rates. There are no randomized comparisons of different hemoclips for bleeding Dieulafoy's lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIVERTICULAR BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only case series have described experience with endoclips in diverticular bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. These have suggested that they may provide as effective hemostasis as thermal coagulation, but there is decreased perforation risk, particularly for lesions at the base of the diverticulum where the wall is thin. An additional benefit of endoclip application, is the potential to serve as a marker if rebleeding occurs and repeat colonoscopy, angiography, or surgery is required. However, other methods (such as tattooing) may be more reliable if permanent marking is desired. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30519?source=see_link\">",
"     \"Tattooing and other methods for localizing colonic lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the reports described the application of endoclips either directly to bleeding vessels within the diverticula or across the mouth of the diverticulum to pinch it closed. Endoclips placed at the base of the diverticulum may pose less of a risk of perforation compared with thermal coagulation therapy.",
"   </p>",
"   <p>",
"    There are settings in which the bleeding point or stigmata cannot be clipped directly or where the stigmata is at the mouth or neck of the diverticulum. In such cases, the diverticulum can be closed with endoclips. There are several methods to accomplish this. As a general rule, the jaws of the endoclip should be able to traverse the width of the diverticulum. However, if the diverticulum is large, longer endoclips may be used or endoclips may be initially applied in a sequential fashion from one side of the diverticulum, gradually \"zipping\" the mouth closed. Several endoclips, in order to close the diverticulum effectively, are usually required. Injection of dilute epinephrine (eg, 1:20,000 in normal saline) prior to the application of an endoclip may assist with hemostasis and by everting the base of the diverticulum, thereby making stigmata more accessible (",
"    <a class=\"graphic graphic_picture graphicRef60007 \" href=\"UTD.htm?1/40/1668\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     POSTPOLYPECTOMY BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoclips have been used for postpolypectomy bleeding and to prevent postpolypectomy bleeding in high-risk settings. However, there have been few studies.",
"   </p>",
"   <p>",
"    Endoclips were effective in controlling immediate postpolypectomy bleeding in most patients in two series with a total of 119 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Despite these excellent results, there are no comparative studies of clipping versus thermal modalities. Prophylactic use of endoclips for prevention of bleeding has also been proposed but its efficacy is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=see_link\">",
"     \"Endoscopic removal of large colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed postpolypectomy bleeding is usually caused by ulceration at the site of the polypectomy. These bleeding lesions can be treated similar to ulcers as described in the previous sections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;In acute postpolypectomy bleeds, there are several possible approaches to the effective application of an endoclip. When the bleeding is from the stump of a pedunculated polyp, the endoclip is usually most effective when placed across the stalk base. This ligates the feeding vessels responsible for the bleeding. For bleeding from sessile polyps that were resected via piecemeal or saline-assisted polypectomy, the endoclip is applied directly to the bleeding site first. After control of hemorrhage, endoclips can be used to close the mucosal defect, if it is large or oozing. However, the benefit of fully closing the defect in such cases has not yet been established (",
"    <a class=\"graphic graphic_picture graphicRef75449 \" href=\"UTD.htm?36/1/36882\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PERFORATIONS AND FISTULAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoclips have been used successfully in patients with gastrointestinal perforations from various causes. Case reports include treatment of perforations from fish bone ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/29\">",
"     29",
"    </a>",
"    ], Boerhaave's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/30\">",
"     30",
"    </a>",
"    ], endoscopic mucosal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/31-34\">",
"     31-34",
"    </a>",
"    ], biliary sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], duodenal polypectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/37\">",
"     37",
"    </a>",
"    ], and colonoscopies (",
"    <a class=\"graphic graphic_picture graphicRef77061 \" href=\"UTD.htm?2/59/2996\">",
"     picture 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Endoclips have also been used to manage postoperative leaks and fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforations should be closed as quickly as possible to prevent contamination. The first clip is usually deployed at one end of the perforation, with subsequent clips applied sequentially across the mucosal defect. Multiple endoclips are usually required.",
"   </p>",
"   <p>",
"    Although endoclips may have a role in the closure of acute perforations, surgery is still the mainstay of clinically significant perforations that are chronic or complicated by contamination or infection. Surgical intervention should be considered strongly if the perforation cannot be closed quickly. Management of such patients is often best done in coordination with a consulting surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoclips have been used creatively in a variety of other situations that are not yet widely accepted or attempted. Case reports have described the use of endoclips to secure jejunal feeding tubes and other stents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14712/abstract/42\">",
"     42",
"    </a>",
"    ]. They may also have a role as a marker to permit identification of a lesion as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Endoscopic clips are a mechanical clamping method that has many potential therapeutic applications. While currently available clips are relatively easy to use, they require specific practice on the part of both the endoscopist and the assistant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Peptic ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective hemostasis with endoclips depends on the ulcer location, ulcer size and type, and the operator and assistant expertise. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Bleeding peptic ulcers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grasp and release endoclips are easier to use in emergencies",
"     </li>",
"     <li>",
"      For severe active bleeding, target irrigation and epinephrine injection aid in visualization of the bleeding point before hemoclipping",
"     </li>",
"     <li>",
"      Ulcers on the lesser curvature, the posterior duodenum, or the cardia increase the difficulty of deployment and clip failure rates",
"     </li>",
"     <li>",
"      Larger endoclips have advantages over smaller hemoclips for hemostasis of chronic ulcers and closure of larger lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mallory-Weiss tears",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoclips can be used to control active bleeding from Mallory-Weiss tears as effectively as injection therapy in Mallory-Weiss tears. Although there have been few studies, they have theoretical advantages compared with other methods. They do not cause significant tissue damage, they permit rapid tissue apposition, and have a low risk of perforation. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Mallory-Weiss tears'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The endoclip should be applied so that the sides of the tear are closed and the bleeding stops",
"     </li>",
"     <li>",
"      If endoclips cannot be effectively placed, thermal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      injection techniques should be used for hemostasis",
"     </li>",
"     <li>",
"      Larger or multiple endoclips may be necessary for closure and hemostasis of longer or deeper tears",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Dieulafoy's lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoclips can control acute bleeding from Dieulafoy's lesions and may reduce rebleeding rates compared with injection therapy. There are no large studies comparing it to thermal or combination therapies. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Dieulafoy's lesions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Good positioning is vital for effective clip placement on the bleeding artery. Effective hemoclip deployment will be less likely if the jaws are in a tangential position.",
"     </li>",
"     <li>",
"      The jaws of the endoclip should be placed across the bleeding Dieulafoy lesion whenever possible.",
"     </li>",
"     <li>",
"      There should be enough tissue grasped around the bleeding vessel, so that strong mechanical hemostatic pressure can be applied.",
"     </li>",
"     <li>",
"      Grasp and release or larger endoclips are easier to deploy and appear to be more effective for actively bleeding Dieulafoy's lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Diverticular bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to thermal coagulation, endoclips may provide similar hemostasis for diverticular bleeds and decreased risk of perforation, particularly for stigmata of hemorrhage located at the base of the diverticulum. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diverticular bleeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epinephrine injection therapy prior to clip deployment should be considered, particularly for active bleeding or adherent clots.",
"     </li>",
"     <li>",
"      To close the mouth of the diverticulum, the jaws should be extended so that sufficient soft tissue on either side of mouth can be grasped when the endoclip is deployed.",
"     </li>",
"     <li>",
"      In larger diverticula, long clips can be used or the mouth of the diverticulum may be closed in a sequential zipper fashion from one side of the diverticular opening to the other.",
"     </li>",
"     <li>",
"      If retained, endoclips may act as markers if surgery or angioembolization are required. However, other methods should also be applied via colonoscopy for longer term marking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Postpolypectomy bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoclips are an effective method to control acute postpolypectomy bleeding, as well as potential mucosal defects from the initial procedure. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Postpolypectomy bleeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For acute bleeding from a pedunculated polyp stalk, the endoclip is most effective when deployed across the stalk to ligate the feeding vessels.",
"     </li>",
"     <li>",
"      For bleeds arising from sessile polyps removed via polypectomy, the point of bleeding should be hemoclipped first. Then closure of the mucosal defect can also be done if there is oozing, bleeding, or a concern about delayed healing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Perforations and fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoclips have been used successfully in patients with gastrointestinal perforations from various causes. Perforations should be closed as quickly as possible to prevent contamination. Surgery is still the mainstay of clinically significant perforations that are chronic or complicated by contamination or infection. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Perforations and fistulas'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoclips should be placed in a sequential fashion starting from one end of the perforation and extending across the perforation",
"     </li>",
"     <li>",
"      Prompt closure of an acute perforation is essential to prevent contamination of adjacent organ spaces",
"     </li>",
"     <li>",
"      On occasion, clips may be used in combination with other modalities to manage postoperative leaks or fistulas",
"     </li>",
"     <li>",
"      If endoclips cannot be effectively deployed or the perforation is chronic, large, or contaminated, early surgical intervention should be considered strongly",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/1\">",
"      Hayashi T, Yonezawa M, Kawabara T. The study on staunch clip for the treatment by endoscopy. Gastroenterol Endosc 1975; 17:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/2\">",
"      Kuramata H, et al. Evaluation of gastrofiberscope for treatment (TGF proto-type by Olympus Co). Stomach Intestine 1974; 9:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/3\">",
"      Chan CY, Yau KK, Siu WT, et al. Endoscopic hemostasis by using the TriClip for peptic ulcer hemorrhage: a pilot study. Gastrointest Endosc 2008; 67:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/4\">",
"      Lin HJ, Hsieh YH, Tseng GY, et al. A prospective, randomized trial of endoscopic hemoclip versus heater probe thermocoagulation for peptic ulcer bleeding. Am J Gastroenterol 2002; 97:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/5\">",
"      Jensen DM, Machicado GA, Hirabayashi K. Hemoclipping (CLIP) of chronic ulcers: A randomized prospective study of initial success, CLIP retention rates, and ulcer healing. Gastrointest Endosc 2005; 61:AB174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/6\">",
"      Jensen DM, Machicado GA, Hirabayashi K. Randomized controlled study of 3 different types of hemoclips for hemostasis of bleeding canine acute gastric ulcers. Gastrointest Endosc 2006; 64:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/7\">",
"      Shin EJ, Ko CW, Magno P, et al. Comparative study of endoscopic clips: duration of attachment at the site of clip application. Gastrointest Endosc 2007; 66:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/8\">",
"      Sung JJ, Tsoi KK, Lai LH, et al. Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 2007; 56:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/9\">",
"      Cipolletta L, Bianco MA, Marmo R, et al. Endoclips versus heater probe in preventing early recurrent bleeding from peptic ulcer: a prospective and randomized trial. Gastrointest Endosc 2001; 53:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/10\">",
"      Chou YC, Hsu PI, Lai KH, et al. A prospective, randomized trial of endoscopic hemoclip placement and distilled water injection for treatment of high-risk bleeding ulcers. Gastrointest Endosc 2003; 57:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/11\">",
"      Chung IK, Ham JS, Kim HS, et al. Comparison of the hemostatic efficacy of the endoscopic hemoclip method with hypertonic saline-epinephrine injection and a combination of the two for the management of bleeding peptic ulcers. Gastrointest Endosc 1999; 49:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/12\">",
"      Gevers AM, De Goede E, Simoens M, et al. A randomized trial comparing injection therapy with hemoclip and with injection combined with hemoclip for bleeding ulcers. Gastrointest Endosc 2002; 55:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/13\">",
"      Ljubicic N. Efficacy of endoscopic clipping and long-term follow-up of bleeding Dieulafoy's lesions in the upper gastrointestinal tract. Hepatogastroenterology 2006; 53:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/14\">",
"      Shimoda R, Iwakiri R, Sakata H, et al. Evaluation of endoscopic hemostasis with metallic hemoclips for bleeding gastric ulcer: comparison with endoscopic injection of absolute ethanol in a prospective, randomized study. Am J Gastroenterol 2003; 98:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/15\">",
"      Lin LF, Siauw CP, Ho KS, Tung JC. Endoscopic hemoclip treatment of gastrointestinal bleeding. Chang Gung Med J 2001; 24:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/16\">",
"      Saltzman JR, Strate LL, Di Sena V, et al. Prospective trial of endoscopic clips versus combination therapy in upper GI bleeding (PROTECCT--UGI bleeding). Am J Gastroenterol 2005; 100:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/17\">",
"      Lin HJ, Lo WC, Cheng YC, Perng CL. Endoscopic hemoclip versus triclip placement in patients with high-risk peptic ulcer bleeding. Am J Gastroenterol 2007; 102:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/18\">",
"      Yuan Y, Wang C, Hunt RH. Endoscopic clipping for acute nonvariceal upper-GI bleeding: a meta-analysis and critical appraisal of randomized controlled trials. Gastrointest Endosc 2008; 68:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/19\">",
"      Yamaguchi Y, Yamato T, Katsumi N, et al. Endoscopic hemoclipping for upper GI bleeding due to Mallory-Weiss syndrome. Gastrointest Endosc 2001; 53:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/20\">",
"      Huang SP, Wang HP, Lee YC, et al. Endoscopic hemoclip placement and epinephrine injection for Mallory-Weiss syndrome with active bleeding. Gastrointest Endosc 2002; 55:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/21\">",
"      Chung IK, Kim EJ, Lee MS, et al. Bleeding Dieulafoy's lesions and the choice of endoscopic method: comparing the hemostatic efficacy of mechanical and injection methods. Gastrointest Endosc 2000; 52:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/22\">",
"      Park CH, Sohn YH, Lee WS, et al. The usefulness of endoscopic hemoclipping for bleeding Dieulafoy lesions. Endoscopy 2003; 35:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/23\">",
"      Hokama A, Uehara T, Nakayoshi T, et al. Utility of endoscopic hemoclipping for colonic diverticular bleeding. Am J Gastroenterol 1997; 92:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/24\">",
"      Rino Y, Imada T, Iwasaki H, et al. Hemostasis of colonic diverticular bleeding with hemoclips under endoscopic control: report of a case. Hepatogastroenterology 1999; 46:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/25\">",
"      Simpson PW, Nguyen MH, Lim JK, Soetikno RM. Use of endoclips in the treatment of massive colonic diverticular bleeding. Gastrointest Endosc 2004; 59:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/26\">",
"      Binmoeller KF, Thonke F, Soehendra N. Endoscopic hemoclip treatment for gastrointestinal bleeding. Endoscopy 1993; 25:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/27\">",
"      Parra-Blanco A, Kaminaga N, Kojima T, et al. Hemoclipping for postpolypectomy and postbiopsy colonic bleeding. Gastrointest Endosc 2000; 51:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/28\">",
"      Sobrino-Faya M, Mart&iacute;nez S, G&oacute;mez Balado M, et al. Clips for the prevention and treatment of postpolypectomy bleeding (hemoclips in polypectomy). Rev Esp Enferm Dig 2002; 94:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/29\">",
"      Shimamoto C, Hirata I, Umegaki E, Katsu K. Closure of an esophageal perforation due to fish bone ingestion by endoscopic clip application. Gastrointest Endosc 2000; 51:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/30\">",
"      Raymer GS, Sadana A, Campbell DB, Rowe WA. Endoscopic clip application as an adjunct to closure of mature esophageal perforation with fistulae. Clin Gastroenterol Hepatol 2003; 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/31\">",
"      Shimizu Y, Kato M, Yamamoto J, et al. Endoscopic clip application for closure of esophageal perforations caused by EMR. Gastrointest Endosc 2004; 60:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/32\">",
"      Tsunada S, Ogata S, Ohyama T, et al. Endoscopic closure of perforations caused by EMR in the stomach by application of metallic clips. Gastrointest Endosc 2003; 57:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/33\">",
"      Yoshikane H, Hidano H, Sakakibara A, et al. Endoscopic repair by clipping of iatrogenic colonic perforation. Gastrointest Endosc 1997; 46:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/34\">",
"      Minami S, Gotoda T, Ono H, et al. Complete endoscopic closure of gastric perforation induced by endoscopic resection of early gastric cancer using endoclips can prevent surgery (with video). Gastrointest Endosc 2006; 63:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/35\">",
"      Baron TH, Gostout CJ, Herman L. Hemoclip repair of a sphincterotomy-induced duodenal perforation. Gastrointest Endosc 2000; 52:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/36\">",
"      Katsinelos P, Paroutoglou G, Papaziogas B, et al. Treatment of a duodenal perforation secondary to an endoscopic sphincterotomy with clips. World J Gastroenterol 2005; 11:6232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/37\">",
"      Charabaty-Pishvaian A, Al-Kawas F. Endoscopic treatment of duodenal perforation using a clipping device: case report and review of the literature. South Med J 2004; 97:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/38\">",
"      Heldwein W, Dollhopf M, R&ouml;sch T, et al. The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies. Endoscopy 2005; 37:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/39\">",
"      Mana F, De Vogelaere K, Urban D. Iatrogenic perforation of the colon during diagnostic colonoscopy: endoscopic treatment with clips. Gastrointest Endosc 2001; 54:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/40\">",
"      Taku K, Sano Y, Fu KI, Saito Y. Iatrogenic perforation at therapeutic colonoscopy: should the endoscopist attempt closure using endoclips or transfer immediately to surgery? Endoscopy 2006; 38:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/41\">",
"      Merrifield BF, Lautz D, Thompson CC. Endoscopic repair of gastric leaks after Roux-en-Y gastric bypass: a less invasive approach. Gastrointest Endosc 2006; 63:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14712/abstract/42\">",
"      Frizzell E, Darwin P. Endoscopic placement of jejunal feeding tubes by using the Resolution clip: report of 2 cases. Gastrointest Endosc 2006; 64:454.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2668 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14712=[""].join("\n");
var outline_f14_23_14712=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AVAILABLE CLIPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRINCIPLES OF HEMOSTASIS, TISSUE APPOSITION, AND RETENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERAL PRINCIPLES OF APPLICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BLEEDING PEPTIC ULCERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Special situations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MALLORY-WEISS TEARS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIEULAFOY'S LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIVERTICULAR BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POSTPOLYPECTOMY BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PERFORATIONS AND FISTULAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MISCELLANEOUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mallory-Weiss tears",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Dieulafoy's lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Diverticular bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Postpolypectomy bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Perforations and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2668\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2668|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/22/28001\" title=\"picture 1\">",
"      Olympus QuickClip2 endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/61/15314\" title=\"picture 2\">",
"      Boston Sci Res Clips endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/34/26146\" title=\"picture 3\">",
"      Cook TriClip endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/57/30612\" title=\"picture 4\">",
"      Endoclip bleeding DU endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/40/1668\" title=\"picture 5\">",
"      Divert bleed endoclip endos",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/1/36882\" title=\"picture 6\">",
"      Endoclip polypec ulcer endo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/59/2996\" title=\"picture 7\">",
"      Fistula closure clip endos",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2668|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/8/29835\" title=\"table 1\">",
"      Available endoclips",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=related_link\">",
"      Endoscopic removal of large colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43317?source=related_link\">",
"      Mallory-Weiss syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30519?source=related_link\">",
"      Tattooing and other methods for localizing colonic lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=related_link\">",
"      Uncommon causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_23_14713="Parapsoriasis large plaque";
var content_f14_23_14713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68028%7ECALC%2F86681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68028%7ECALC%2F86681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large plaque parapsoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous patches with minimal scale that are several centimeters in diameter are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large-plaque parapsoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Widespread dark brown patches in a patient with large plaque parapsoriasis.&nbsp;",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14713=[""].join("\n");
var outline_f14_23_14713=null;
var title_f14_23_14714="Pharmacologic therapy of osteoarthritis";
var content_f14_23_14714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacologic therapy of osteoarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/23/14714/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14714/contributors\">",
"     Kenneth C Kalunian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/23/14714/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14714/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/23/14714/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/23/14714/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/23/14714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 6, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis (OA) is a frequent cause of joint pain and is estimated to be the most common cause of disability in adults. A systematic review of incidence and prevalence of OA of the knee in persons older than 55 years in the United Kingdom reported an incidence of 25 percent per year, a prevalence of disability due to knee OA of 10 percent, and severe disability in about two to three percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goals of management of patients with osteoarthritis (OA) are to control pain and swelling, minimize disability, improve the quality of life, and educate the patient about his or her role in the management team. Management should be individualized to the patient's expectations, level of function and activity, to the joints involved and the severity of the patient's disease, to occupational and vocational needs, and to the nature of any coexisting medical problems. Subjective complaints and objective findings may guide the clinician in designing appropriate therapeutic goals.",
"   </p>",
"   <p>",
"    There are, at present, no specific pharmacologic therapies that can prevent the progression of joint damage due to OA. The goal of finding disease modifying agents for OA that can prevent radiographic joint space narrowing, indicative of progressive articular cartilage loss is being addressed through ongoing research. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=see_link\">",
"     \"Investigational approaches to the pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain and other symptoms of OA can be confused with soft tissue processes such as bursitis at periarticular sites; in addition, pain in a particular area may be referred from OA at other site or may be due to a nonarticular process. Thus, an important first step in management is to reasonably certain that pain in a particular joint is indeed due to OA at that site.",
"   </p>",
"   <p>",
"    The American College of Rheumatology (ACR) has developed classification criteria for OA of the hip [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/2\">",
"     2",
"    </a>",
"    ], knee [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/3\">",
"     3",
"    </a>",
"    ], and hand [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/4\">",
"     4",
"    </a>",
"    ] to assist the clinician in identifying patients with symptomatic OA of these areas. Classification criteria for other areas have not been developed but a rheumatologist can be helpful in difficult situations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link\">",
"     \"Diagnosis and classification of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of the authors' therapeutic approach to patients with OA is outlined in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef75993 \" href=\"UTD.htm?25/25/26015\">",
"     algorithm 1",
"    </a>",
"    ). These guidelines are for patients with both noninflammatory and inflammatory OA.",
"   </p>",
"   <p>",
"    Guidelines for the management of specific sites of OA have also been developed by members of the ACR for the hip [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/5\">",
"     5",
"    </a>",
"    ] and the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/6\">",
"     6",
"    </a>",
"    ]. An updated set of recommendations for both hip and knee involvement is available at the following web address [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"    <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/guidelines/oa-mgmt.asp\">",
"     www.rheumatology.org/practice/clinical/guidelines/oa-mgmt.asp",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Variations in these guidelines are required for certain sites of involvement; as an example, not all joints are amenable to arthroscopic irrigation or synovectomy and arthroplasty cannot be performed on many joints.",
"   </p>",
"   <p>",
"    Both inflammatory and noninflammatory OA can be polyarticular, pauciarticular, or monoarticular. There are, however, differences in symptoms and physical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with noninflammatory OA generally have pain and disability-related complaints as their only symptoms. Physical findings in affected joints include tenderness, bony prominence, and crepitus.",
"     </li>",
"     <li>",
"      Patients with inflammatory OA complain of articular swelling, morning stiffness lasting for more than 30 minutes, and night pain. Signs of inflammation include joint effusion on examination or radiography, warmth on palpation of the joint, and synovitis on arthroscopic examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major pharmacologic modalities used in the treatment of OA, including analgesics, nonsteroidal antiinflammatory drugs (NSAIDs), intraarticular glucocorticoids, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , Joint irrigation and surgical approaches to the treatment of OA and are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"     \"Surgical therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic therapies for OA of the knee for which there is reasonably strong evidence of efficacy include exercise programs, weight loss, patient education, and wedged shoe insoles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/9\">",
"     9",
"    </a>",
"    ]. Nonpharmacologic interventions, other than surgical approaches, are generally begun before medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acupuncture and alternative and complementary therapies are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7607?source=see_link\">",
"     \"Acupuncture for rheumatic conditions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7513?source=see_link\">",
"     \"Complementary and alternative remedies in rheumatic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dietary supplements (eg, glucosamine and chondroitin) are addressed in the reviews of investigational approaches to treatment of OA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=see_link\">",
"     \"Investigational approaches to the pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with OA are well managed by a primary care physician; however, some patients with severe symptoms may require referral to a subspecialist. Consultation with a rheumatologist may be helpful if the diagnosis is in doubt and assistance with needle aspiration or injection is needed. Consultation may also be prudent for patients requiring narcotic analgesics, in whom the diagnosis should be confirmed and suggestions for alternative treatments sought. Patients with severe OA unrelieved by conservative therapies may require orthopedic consultation and surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANALGESICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain relief is the primary indication for the use of pharmacologic agents in patients with OA who do not respond to nonpharmacologic interventions. In patients with noninflammatory OA, this goal is generally achieved by the administration of a non-opioid, simple analgesic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonprescription analgesic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen (paracetamol)",
"    </a>",
"    at doses of up to 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (eg, 1000 mg three times a day or 650 mg every six hours) is the drug of choice for pain relief in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. A 2006 meta-analysis of 15 randomized trials found evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is superior to placebo, but less effective in relieving pain due to OA of the hip or knee than NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Oral NSAIDs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Adverse effects of therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    are generally mild. Hepatotoxicity can occur but, at these doses, is primarily seen only in patients who concurrently consume excessive amounts of alcohol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    in doses of 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or greater can increase the risk for gastrointestinal (GI) complications, including bleeding and perforation, but these complications are not increased at lower acetaminophen doses. Additionally, the risk of GI complications is greater with the combination of acetaminophen and an NSAID than with either alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link&amp;anchor=H4#H4\">",
"     \"Unusual causes of peptic ulcer disease\", section on 'Acetaminophen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is suggestive but not definitive evidence that chronic, especially daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    use has dose-dependent, long-term nephrotoxicity. The supportive data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35335?source=see_link&amp;anchor=H3#H3\">",
"     \"Risk factors for and pathogenesis of analgesic nephropathy\", section on 'Acetaminophen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Opioid analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid analgesics, such as codeine or oxycodone, should be avoided for long-term use. However, these agents may be beneficial for short-term use in patients with acute exacerbations of pain. In a controlled study, a long acting narcotic, oxycodone, was synergistic with NSAIDs for reducing pain in patients with OA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients with OA are &ge;65 years of age and some are much older. In the geriatric population the use of opioid analgesics for noncancer pain is discouraged due to increased sensitivity to adverse side effects, particularly sedation, confusion, and constipation.",
"   </p>",
"   <p>",
"    Tramadol alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may also be useful when added to ongoing treatment with an NSAID or COX-2 inhibitor. A 2006 meta-analysis assessed the efficacy of tramadol or tramadol plus acetaminophen in OA using data from 11 randomized placebo-controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/13\">",
"     13",
"    </a>",
"    ]. The overall difference in the mean change in pain between the tramadol and placebo groups was significantly greater for those who received tramadol (mean difference -8.5 units).",
"   </p>",
"   <p>",
"    The combination of tramadol and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (37.5",
"    <span class=\"nowrap\">",
"     mg/325",
"    </span>",
"    mg) is roughly equivalent to 30 mg codeine and 325 mg of acetaminophen. This was the conclusion of a controlled study of 462 patients with chronic pain of various etiologies; 162 patients had OA and 188 OA and chronic low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/14\">",
"     14",
"    </a>",
"    ]. Two-thirds were randomly assigned to the",
"    <span class=\"nowrap\">",
"     tramadol/acetaminophen",
"    </span>",
"    combination and one-third to",
"    <span class=\"nowrap\">",
"     codeine/acetaminophen;",
"    </span>",
"    pain relief achieved with each combination was similar (pain scores changed by 11.9 and 11.4, respectively). Somnolence and constipation were more frequent adverse effects in the group receiving codeine while headache was more common in those receiving tramadol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arguments have also been made for the use of opioids in patients who are not candidates for surgery and who continue to have moderate to severe pain despite being administered NSAIDs or selective cyclooxygenase (COX)-2 inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/15\">",
"     15",
"    </a>",
"    ]. Narcotics may also be considered for patients who are at high risk for adverse effects of both selective COX-2 inhibitors and nonselective NSAIDs. The ACR and EULAR guidelines on treatment of knee OA support the use of opioids when other treatments have failed or are not appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The U.S. Food and Drug Administration (FDA) has recommended against continued prescribing and use of propoxyphene, an opioid analgesic that has been used in the past; the FDA has requested that it be withdrawn from the market in the U.S. because of findings that use at recommended levels results in important changes in cardiac electrical activity, which can increase risk for serious cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NONSTEROIDAL ANTIINFLAMMATORY DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonsteroidal antiinflammatory drug (NSAID) may be indicated in patients with noninflammatory OA who fail to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or for those with moderate to severe pain. The majority of experience is with oral administration of NSAIDs, but in some countries, topical preparations are available.",
"   </p>",
"   <p>",
"    In addition, NSAIDs should be given prior to oral analgesics in patients with inflammatory OA who do not respond to nonpharmacologic interventions. The demonstration of superinduction of prostaglandin E2 in human OA cartilage suggests that PGE2 may contribute to the local inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/17,18\">",
"     17,18",
"    </a>",
"    ] and provides a specific rationale for the use of NSAIDs in inflammatory OA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oral NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs are effective pain relievers in patients with OA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/19\">",
"     19",
"    </a>",
"    ]. The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    has also been demonstrated to be superior to placebo in relief of pain due to OA, but is less effective than NSAIDs. The evidence for this was provided by a 2004 meta-analysis of 15 randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      was more effective than placebo in relieving pain due to OA of the hip",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      knee. The difference in pain relief was small but significant (standard mean difference [SMD] -0.13, 95% CI 0.22-0.03). This corresponded to a difference of approximately 5 percent in the mean of multiple measures of pain and was of questionable clinical importance.",
"     </li>",
"     <li>",
"      For rest pain and for pain with motion there was no significant difference between the small beneficial effects observed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      compared to NSAIDs; SMDs - 0.19 and -0.20 for rest pain, and SMDs of - 0.03 and - 0.04 for pain with motion.",
"     </li>",
"     <li>",
"      NSAIDs were more efficacious than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      in relieving overall pain as measured using the pain scale of the Western Ontario and McMasters Universities osteoarthritis index (WOMAC). The SMDs for WOMAC pain were -0.37 (95% CI -.050 to -0.24) and -0.24 (95% CI -.38 to -0.09), respectively. The difference between the means for NSAIDs and acetaminophen was similar to that for acetaminophen when compared to placebo.",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms were more frequent with use of nonselective NSAIDs than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (relative risk 1.47, 95% CI 1.08-2.00). The risk of adverse gastrointestinal events with COX-2 selective agents was not significantly different from the risk with acetaminophen (RR 0.98, 95% CI 0.80-1.20).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ACR treatment guidelines for OA support the use of NSAIDs in conjunction with nonpharmacologic measures for some",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -naive patients, particularly those with more severe pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/7\">",
"     7",
"    </a>",
"    ]. EULAR guidelines recommend NSAIDs for those with OA of the knee who have had inadequate relief of pain with acetaminophen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many different NSAIDs can be used in patients with symptomatic OA, including over-the-counter agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ) and prescription drugs (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"     table 1",
"    </a>",
"    ). There is immense variability in patients' responses to the different agents in terms of both efficacy and toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (less than 1600",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      may have less serious gastrointestinal toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H3#H3\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Nonselective NSAIDs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonacetylated salicylates (salsalate, choline magnesium trisalicylate), sulindac, and perhaps nabumetone appear to have less renal toxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The nonacetylated salicylates and nabumetone have less antiplatelet activity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Indomethacin should probably be avoided for long-term use in patients with hip OA since it may be associated with accelerated joint destruction in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The selective cyclooxygenase-2 (COX-2) inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      and etoricoxib) appear to be as effective as the traditional nonspecific NSAIDs. Although they are associated with less gastroduodenal toxicity, concerns about an increased risk of cardiovascular adverse events has limited their use. Furthermore, the concomitant use of low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      for an antithrombotic effect may negate the gastroduodenal sparing effects of COX-2 inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'COX-2 inhibitors'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients at increased risk of gastroduodenal damage who are receiving low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and a COX-2 selective agent may benefit from antiulcer prophylaxis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Topical NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The topical application of NSAIDs may reduce the risk of side-effects that are seen with oral use. However, topical NSAIDs, such as topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    , are available in only some countries. Thus, topical use of NSAIDs is discussed along with other investigational therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=see_link&amp;anchor=H34171215#H34171215\">",
"     \"Investigational approaches to the pharmacologic therapy of osteoarthritis\", section on 'Topical NSAIDs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     COX-2 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;These drugs have at least a 200- to 300-fold selectivity for inhibition of COX-2 over COX-1. However, two selective COX-2 inhibitors, rofecoxib and valdecoxib, have been withdrawn from the worldwide market because of an increased risk of serious cardiovascular adverse events associated with their use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link&amp;anchor=H2#H2\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\", section on 'Ischemic cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe that the use of selective COX-2 inhibitors (coxibs) cannot be justified simply because of the potential reduction in gastrointestinal risks. Increased cardiovascular risks precludes use of coxibs unless the gastrointestinal risk is very high, the cardiovascular risk is low (eg, no known cardiovascular disease and absence of multiple cardiovascular risk factors), some NSAID therapy is considered unavoidable, and the patient is informed of the potential benefits and risks of coxib use.",
"   </p>",
"   <p>",
"    As an example, selective COX-2 inhibitors are an option for patients at low cardiovascular risk who have a history of peptic ulcer, gastrointestinal bleeding, or gastrointestinal intolerance to NSAIDs (including salicylates) and whose joint pain is inadequately controlled using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . An alternative approach is the use of a nonselective NSAID and a gastroprotective agent such as a proton pump inhibitor or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Selective COX-2 inhibitors are not effective as prophylactic therapy for ulcers. Thus, in patients with a history of peptic ulcer disease that was unrelated to NSAID use, continued use of effective antiulcer agents, such as a proton pump inhibitor, may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Maintenance therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of a COX-2 selective agent and low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    conveys a similar risk of gastroduodenal ulceration and ulcer complications as does the use of a nonselective NSAID [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, a patient who needs low dose aspirin for primary or secondary prevention of coronary artery or cerebrovascular disease and has risk factors for gastroduodenal damage from NSAIDs also needs antiulcer prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAID use is often limited by toxicity. Among the side effects that can occur are [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/20,25\">",
"     20,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rash and hypersensitivity reactions",
"     </li>",
"     <li>",
"      Abdominal pain and gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Impairment of renal, hepatic, and bone marrow function, and platelet aggregation",
"     </li>",
"     <li>",
"      Central nervous system dysfunction in the elderly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These adverse reactions are discussed in detail elsewhere. However, it is useful to briefly review those settings in which either NSAIDs should be avoided or a particular NSAID preferably used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSAIDs are contraindicated in patients with active peptic ulcer disease. Nonselective NSAIDs should be avoided in patients with a history of peptic ulcer disease. Selective COX-2 inhibitors are preferred in these individuals.",
"     </li>",
"     <li>",
"      Nonselective NSAIDs must be used with caution in patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      . Although there is no significant alteration in the effect of warfarin on prothrombin activity, NSAID-induced platelet dysfunction can increase the risk of bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/26\">",
"       26",
"      </a>",
"      ]. By comparison, selective COX-2 inhibitors can be considered in this setting in patients at low cardiovascular risk.",
"     </li>",
"     <li>",
"      Patients with intrinsic renal disease, heart failure, or cirrhosis, and those receiving diuretic therapy are at risk for developing reversible renal failure while using an NSAID. In these settings, the synthesis of vasodilator renal prostaglandins helps to maintain renal perfusion. Interfering with this protective response with an NSAID can lead to renal ischemia and an elevation in the plasma creatinine concentration. Nonacetylated salicylates and sulindac in low doses appear to relatively spare renal prostaglandin synthesis and can be used with caution in such patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NSAIDs may interfere with the control of hypertension, usually resulting in a modest rise in blood pressure of approximately 5 mmHg. This effect should be anticipated and antihypertensive agents adjusted accordingly or alternatives to NSAIDs can be used [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=see_link\">",
"       \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      and some other NSAIDs can interfere with the desirable antiplatelet effects of low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . The relevant data are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients with diminished cardiac function may develop overt heart failure when challenged with NSAIDs [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NSAIDs should",
"    <strong>",
"     not",
"    </strong>",
"    be used in combination because of the greater risk of adverse events and the lack of evidence that the use of two or more NSAIDs is associated with improved efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NSAIDs should be avoided in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/5\">",
"     5",
"    </a>",
"    ]. The selective COX-2 inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , may be less likely to provoke symptoms in aspirin sensitive reactive airways disease. This issue is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Choice of NSAID",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no convincing evidence that any of the available NSAIDs is more effective than any other for osteoarthritis of the knee or hip [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Thus, the choice of a NSAID is based upon a variety of other factors including adverse effect profile, cost, type of OA, and frequency of dosage.",
"   </p>",
"   <p>",
"    It is preferable to use a NSAID on a periodic basis in patients with noninflammatory OA since the presence and intensity of symptoms usually vary with time; a short-acting agent is ideal in this setting&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/5\">",
"     5",
"    </a>",
"    ]. Continuous therapy is indicated if this regimen does not provide adequate symptom control. Because of the pathophysiology, continuous NSAID therapy should be used in patients with inflammatory osteoarthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally recommend the following approach when selecting from the available NSAIDs and COX-2 selective agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A short-acting NSAID is generally used initially. Due to cost considerations, an over-the-counter agent (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      ) is a reasonable choice. It usually takes about",
"      <strong>",
"       two to four weeks",
"      </strong>",
"      to evaluate the efficacy of a NSAID [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If there is inadequate control with the initial dose, then the dose should be gradually increased toward the maximum for that drug (",
"      <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"       table 1",
"      </a>",
"      ). The patient should be monitored more closely as the dose is increased, and should be educated to monitor for symptoms indicative of side effects.",
"     </li>",
"     <li>",
"      If one NSAID is not effective after two to four weeks on a maximal dosage, then another NSAID or nonacetylated salicylate should be tried.",
"     </li>",
"     <li>",
"      If there is a history of gastroduodenal disease, a selective COX-2 inhibitor may be considered in patients at low cardiovascular risk or a nonselective NSAID can be combined with antiulcer prophylaxis.",
"     </li>",
"     <li>",
"      When NSAID use is considered, the patient should be informed of the potential cardiovascular risk. The relative cardiovascular risks of different NSAIDs are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"       \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative gastrointestinal toxicity of different NSAIDs and the methods that may be used to prevent NSAID-induced gastroduodenal damage are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INTRAARTICULAR GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarticular glucocorticoid injections may be appropriate in patients with OA who have one or a few joints that are painful despite the use of an NSAID, and in patients with monoarticular or pauciarticular inflammatory osteoarthritis in whom NSAIDs are contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraarticular glucocorticoids slow cartilage catabolism and osteophyte formation in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]; they are also effective for short-term pain relief and can increase quadriceps strength after knee injection. A year 2004 meta-analysis of",
"    <span class=\"nowrap\">",
"     placebo/sham",
"    </span>",
"    controlled trials found those receiving glucocorticoid injections for OA of the knee to be twice as likely as controls to have short term improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/36\">",
"     36",
"    </a>",
"    ]. A randomized, placebo-controlled trial of fluoroscopically guided glucocorticoid injection for osteoarthritis of the hip demonstrated benefits lasting up to three months in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of glucocorticoid injections at sites other than the knee or hip is less certain. As an example, 40 patients with carpometacarpal (CMC) joint arthritis of the thumb were randomly assigned to receive a single injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide (0.25 mL) or saline [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/38\">",
"     38",
"    </a>",
"    ]. Both the steroid and saline-injected groups had decreased pain, but there was no apparent advantage for the steroid injection at any time point and the mean self-reported pain was identical in the two groups at 24 weeks. Unfortunately, enrollment in this study was about one-half of that needed based upon a statistical power calculation at the outset. Thus, the possibilities remain that steroid injection of the CMC joint of the thumb may result in clinically significant benefit or that the clinical benefit is entirely a placebo effect of the injection procedure itself.",
"   </p>",
"   <p>",
"    Repeated glucocorticoid injections over a period up to two years appear to be safe, and may provide more relief than saline injections. This was illustrated in a study that randomly assigned 68 patients with OA of the knees to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    (40 mg) or saline solution intra-articularly every 3 months and assessed joint space narrowing, pain and function over two years of study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/39\">",
"     39",
"    </a>",
"    ]. There were no significant differences in the rate of joint space narrowing, and no significant differences in the level of pain at the end of the study. However, when the pain scores were summed over the two-year period, the group that received saline had a nonsignificant trend toward less cumulative pain relief than those given steroids (0.32 versus 0.64, respectively). No joint infections and no acute \"flares\" of joint pain were noted in either group.",
"   </p>",
"   <p>",
"    The use of aseptic technique is essential to minimize the risk of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    .) Fluid, if aspirated, should be sent for cell count, Gram stain, and culture if an infection is suspected. The joint should not be injected until there is certainty that an infection is not present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/40\">",
"     40",
"    </a>",
"    ]. Clinical findings suggestive of possible joint infection include fever, leukocytosis, or the rapid onset of a large effusion.",
"   </p>",
"   <p>",
"    Glucocorticoids formulated for intraarticular injection are in crystalline suspension; the crystals rarely lead to a transient mild flare of synovitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28564?source=see_link\">",
"     \"Joint aspiration or injection in adults: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common synthetic glucocorticoid suspensions used for intraarticular injection include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide, triamcinolone hexacetonide, and microcrystalline",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    . The amount of these agents generally used depends upon joint size:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      10 mg for small joints (interphalangeal, metacarpophalangeal, and metatarsophalangeal joints)",
"     </li>",
"     <li>",
"      20 mg for medium-sized joints (wrists, elbows, ankles, and acromioclavicular joints)",
"     </li>",
"     <li>",
"      40 mg for larger joints (shoulders, knees, hips).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of intraarticular glucocorticoids in hip osteoarthritis has not been studied. This is a technically difficult procedure which generally requires fluoroscopic guidance under the direction of a rheumatologist, orthopedist, or radiologist [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INTRAARTICULAR HYALURONANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of intraarticular hyaluronans in OA have been the subject of a number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/41-56\">",
"     41-56",
"    </a>",
"    ]. Their aim has been to determine whether intraarticular supplementation of these macromolecules, which are deficient in degenerative cartilage, can lead to decreased symptoms of osteoarthritis. The available evidence suggests that intraarticular hyaluronans may have a small pain relieving advantage when compared with intraarticular placebo injections or oral NSAID therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/56\">",
"     56",
"    </a>",
"    ]. In some studies they are comparable to intraarticular glucocorticoids. There may be subpopulations of patients with osteoarthritis that respond well to this type of therapy.",
"   </p>",
"   <p>",
"    Commercial hyaluronan preparations currently are available in the United States include: sodium hyaluronate (Hyalgan&reg;, Supartz&reg;, and Nuflexxa&reg;), and hylan G-F 20 (Synvisc&reg;).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Knee",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Comparison to intraarticular placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;A year 2003 meta-analysis pooled the results of 22 trials of hyaluronan injections versus intraarticular placebo injections and concluded that hyaluronan injections were superior to the intraarticular saline injections but had a relatively small effect [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/41\">",
"     41",
"    </a>",
"    ]. A year 2005 meta-analysis assessed hyaluronan and placebo groups at various time periods following injection and noted a statistically significant advantage for hyaluronan in rest pain between two and six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/42\">",
"     42",
"    </a>",
"    ]. However, while the mean difference of 8.7 mm on a 100 mm visual analog scale was statistically significant, its clinical importance was questioned. Decreased pain with use was also significantly greater at 10 to 14 weeks and 22 to 30 weeks after injection, but not at earlier or later time periods. Function was not improved by hyaluronan injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Comparison to NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest trial that included an NSAID control randomly assigned 495 patients with osteoarthritis of the knee to one of three treatment groups; a series of five weekly intraarticular injections of hyaluronic acid (Hyalgan&reg;), oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , or a placebo for 26 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/43\">",
"     43",
"    </a>",
"    ]. The group that completed the series of injections had more improvement in knee pain than the placebo group (difference of 8.8 mm on a 100 mm scale). However, there was no statistically significant difference between those who received injections compared to the naproxen group. In addition, a reanalysis of the data from this trial on an intent to treat basis suggested there was no difference between the hyaluronate and placebo groups at either 12 or 26 weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Comparison to intraarticular glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarticular hyaluronic acid injections may provide benefits similar to those provided by intraarticular glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/47,48,55\">",
"     47,48,55",
"    </a>",
"    ]. A systematic review of 28 randomized trials of intraarticular glucocorticoid injections for knee osteoarthritis, involving 1973 patients, compared glucocorticoid injection with hyaluronic acid products, joint lavage, and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/55\">",
"     55",
"    </a>",
"    ]. There were no significant differences between glucocorticoid injections and hyaluronate during the first month; greater benefit of hyaluronate appeared between 5 and 13 weeks postinjection, but was not sustained.",
"   </p>",
"   <p>",
"    The following studies illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 100 patients were randomly assigned to receive a series of three hylan G-F 20 injections or a single injection of betamethasone&nbsp;sodium phosphate and betamethasone acetate (Celestone Soluspan&reg;) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/48\">",
"       48",
"      </a>",
"      ]. There were no statistically significant differences between the two groups in knee pain or function.",
"     </li>",
"     <li>",
"      Another study of 195 patients, presented only in abstract form, suggested a significantly greater benefit from hylan G-F 20 than glucocorticoids in pain relief (reductions of 43 versus 14 percent from baseline) one year after the injections [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger clinical trials are needed to determine whether there is an identifiable subset of patients with OA for whom intraarticular injections of hyaluronic acid derivatives is particularly beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103700731\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postinjection flare, characterized by increased pain, swelling, and the presence of an inflammatory joint effusion is a side effect of hyaluronan joint injection that is seen in from 1.5 to 5 percent of injected knees. Some of these flares may produce pain, swelling, and joint fluid leukocytosis, which may suggest septic arthritis. Joint fluid analysis reveals markedly elevated white blood counts (up to 100,000 per mm3), sterile cultures, and the absence of crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of a postinjection flare may be related to injection technique. In a retrospective review of 336 patients with 1,537 injections administered over the course of 2.5 years, the lowest incidence of postinjection flares (1.5 percent) occurred with injections via a lateral approach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/46\">",
"     46",
"    </a>",
"    ]; by comparison, higher rates of flares were observed with medial approaches with flexed or extended knees (5.2 and 2.4 percent, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28564?source=see_link\">",
"     \"Joint aspiration or injection in adults: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Does molecular weight matter?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct comparison of cross-linked high molecular weight hylan (Synvisc&reg;) to two noncrosslinked medium molecular weight hyaluronan preparations (Orthovisc&reg; and Ostenil&reg;) suggests that injections of a crosslinked high molecular weight product is not more efficacious than solutions containing medium molecular weight hyaluronan. This was illustrated in a study that randomly assigned 660 patients with radiologic and symptomatic OA of the knee to receive three sequential injections of: cross-linked high molecular weight hylan, noncrosslinked medium molecular weight avian hyaluronan, or noncrosslinked low molecular weight hyaluronan [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/50\">",
"     50",
"    </a>",
"    ]. There were no statistically or clinically significant differences apparent in the primary outcome measure of pain, or on any of the secondary outcomes. Serious adverse events occurred in similar proportions of patients in the crosslinked hylan and noncrosslinked hyaluronan groups (6.8 and 5.7 percent, respectively). Further support for similar efficacy of intraarticular hyaluronan preparations regardless of molecular weight was provided by a 2007 systematic review and meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hip",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective study of intraarticular injection of hylan G-F 20 into the hip using fluoroscopic guidance suggests that this approach is feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/52\">",
"     52",
"    </a>",
"    ]. Pain during walking was significantly decreased from baseline following an injection. Hip pain temporarily worsened following 10 percent of injections and transient hip effusions were noted in two instances. An uncontrolled pilot study of hip injection of hylan G-F 20 using ultrasonographic guidance suggests that hyaluronans can be successfully injected into the hip as well as the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/53\">",
"     53",
"    </a>",
"    ]. These promising results need confirmation in a placebo controlled study in order to better assess efficacy and safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25241134\">",
"    <span class=\"h1\">",
"     GLUCOSAMINE AND CHONDROITIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of glucosamine and chondroitin for OA has been controversial, and results of randomized trials have varied [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/57-71\">",
"     57-71",
"    </a>",
"    ]. The balance of evidence from high quality trials has shown little to no evidence of clinically meaningful benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Trials that suggest benefit have been criticized on various methodologic grounds.",
"   </p>",
"   <p>",
"    The following findings are among the most informative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most representative evidence of the limited efficacy of these compounds is a 2010 network meta-analysis of the large randomized trials in patients with OA of the knee or hip that compared glucosamine, chondroitin, or their combination either head-to-head or with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/59\">",
"       59",
"      </a>",
"      ]. This analysis of 10 trials involving 3803 patients found that use of neither the individual drugs nor their combination resulted in clinically significant improvement; such improvement was defined based upon the prespecified minimal clinically significant difference in pain intensity of 0.9 cm on a 10 cm visual analogue scale. No evidence of time-dependent effects was observed. Neither glucosamine sulfate nor glucosamine hydrochloride exhibited clinically relevant benefit.",
"      <br/>",
"      <br/>",
"      The analysis also found that trials that were commercially funded had larger effect sizes than those that were independent of industry. Radiographic changes (minimal width of joint space) with the drugs were also very small, and did not reach statistical significance. The frequency of adverse effects did not differ between the individual drugs and placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of glucosamine and chondroitin sulfate was not significantly more effective than placebo for pain relief or functional improvement in patients with OA of the knee in the GAIT trial, in which 1583 patients with painful OA of the knee were randomly assigned to receive either placebo, glucosamine HCL (500 mg three time daily), chondroitin sulfate (400 mg three time daily), glucosamine plus chondroitin sulfate (500 mg + 400 mg three times daily), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      After 24 weeks of treatment there was no significant difference in the proportion of patients who had at least a 20 percent decrease in pain (a predetermined response) when placebo, glucosamine, chondroitin sulfate, and combination groups were compared [",
"      <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/57\">",
"       57",
"      </a>",
"      ]. The proportion of patients who responded to celecoxib was significantly greater than placebo at this time point (70 versus 60 percent, respectively). A possible benefit of the combination of glucosamine and chondroitin sulfate compared with placebo was suggested in an exploratory subgroup analysis of the 24-week data for patients with moderate to severe pain (20 percent pain reduction in 79 versus 54 percent, respectively).",
"      <br/>",
"      <br/>",
"      However, at two years, none of the treatments resulted in a statistically significant or clinically important difference in pain or function compared with placebo. Adverse events were similar among treatment groups and serious adverse effects were rare.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that glucosamine and chondroitin have little benefit in patients with osteoarthritis. On the other hand, there appear to be few risks associated with their use. If patients want to try these drugs, glucosamine has typically been studied at a dose of 500 mg three times daily, and chondroitin at a dose of 400 mg three times daily. Glucosamine should not be administered to patients who are allergic to shellfish.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COLCHICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basis for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in inflammatory OA that is refractory to NSAIDs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraarticular glucocorticoids is that the majority of such patients have evidence of calcium pyrophosphate dihydrate crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/72\">",
"     72",
"    </a>",
"    ]. Inflammation is attenuated by colchicine via microcrystal-induced tyrosine phosphorylation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in 10 patients with calcium pyrophosphate deposition disease showed a significant decrease in the number of recurrent attacks from a median of 3.2 to 1.0 per year [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    to ongoing NSAID therapy may produce an additional benefit. This was illustrated in a small study in which 36 patients with OA of the knee were randomly assigned to receive nimesulide plus colchicine (0.5 mg twice daily) or nimesulide plus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/75\">",
"     75",
"    </a>",
"    ]. Significantly more patients receiving the NSAID plus colchicine combination had at least 30 percent improvement in osteoarthritis scores (57.9 versus 23.5 percent, respectively).",
"   </p>",
"   <p>",
"    In view of these findings, it may be reasonable to use prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    (0.6 mg twice daily) in patients with OA if the patient has frequent acute inflammatory episodes that do not respond well to NSAIDs, intraarticular steroid injections,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    joint irrigation. Chronic colchicine therapy is generally safe in patients who do not have underlying hepatic or renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ANTIMALARIAL DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydroxychloroquine has been used infrequently in patients with inflammatory or erosive OA. One report retrospectively reviewed charts of patients with erosive OA who were treated with hydroxychloroquine because of symptoms that were unresponsive to NSAIDs; hydroxychloroquine was felt to be effective in six of eight patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/23/14714/abstract/76\">",
"     76",
"    </a>",
"    ]. Prospective, randomized, double-blind studies of large numbers of patients are needed in order to confirm these initial observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"       \"Patient information: Osteoarthritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"       \"Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"       \"Patient information: Osteoarthritis treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/1\">",
"      Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001; 60:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/2\">",
"      Altman R, Alarc&oacute;n G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/3\">",
"      Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/4\">",
"      Altman R, Alarc&oacute;n G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990; 33:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/5\">",
"      Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 1995; 38:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/6\">",
"      Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995; 38:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/7\">",
"      Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/8\">",
"      Concoff AL, Singh R, Klarhman D, et al. A clinical algorithim for identifying occult crystalline disease in patients with osteoarthritis (abstract). Arthritis Rheum 1997; 40:S239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/9\">",
"      Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/10\">",
"      Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006; :CD004257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/11\">",
"      Doherty M, Hawkey C, Goulder M, et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Ann Rheum Dis 2011; 70:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/12\">",
"      Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999; 26:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/13\">",
"      Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev 2006; :CD005522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/14\">",
"      Mullican WS, Lacy JR, TRAMAP-ANAG-006 Study Group. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clin Ther 2001; 23:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/15\">",
"      Peloso PM. Opioid therapy for osteoarthritis of the hip and knee: use it or lose it? J Rheumatol 2001; 28:6.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administaion. Propoxyphene-containing products www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm233800.htm (Accessed on November 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/17\">",
"      Amin AR, Attur M, Patel RN, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest 1997; 99:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/18\">",
"      Li X, Afif H, Cheng S, et al. Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage and chondrocytes. J Rheumatol 2005; 32:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/19\">",
"      Bjordal JM, Ljunggren AE, Klovning A, Sl&oslash;rdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004; 329:1317.",
"     </a>",
"    </li>",
"    <li>",
"     Batchlor EE, Paulus HE. Principles of drug therapy. In: Osteoarthritis: Diagnosis and Medical/Surgical Management, Moskowitz RW, Howell DS, Goldberg VM, Mankin HJ (Eds), WB Saunders Co., Philadelphia 1992. p.465.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/21\">",
"      Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/22\">",
"      Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/23\">",
"      Huskisson EC, Berry H, Gishen P, et al. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis. J Rheumatol 1995; 22:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/24\">",
"      Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/25\">",
"      Coles LS, Fries JF, Kraines RG, Roth SH. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983; 74:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/26\">",
"      Morgan J, Furst DE. Implications of drug therapy in the elderly. Clin Rheum Dis 1986; 12:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/27\">",
"      Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther 1998; 20:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/28\">",
"      Feenstra J, Grobbee DE, Remme WJ, Stricker BH. Drug-induced heart failure. J Am Coll Cardiol 1999; 33:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/29\">",
"      Watson MC, Brookes ST, Kirwan JR, Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database Syst Rev 2000; :CD000142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/30\">",
"      Towheed T, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Cochrane Database Syst Rev 2000; :CD000517.",
"     </a>",
"    </li>",
"    <li>",
"     Newstadt DH. Intraarticular steroid therapy. In: Osteoarthritis: Diagnosis and Medical/Surgical Management, Moskowitz RW, Howell DS, Goldberg VM, Mankin HJ (Eds), WB Saunders Co, Philadelphia 1992. p.493.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/32\">",
"      Wada J, Koshino T, Morii T, Sugimoto K. Natural course of osteoarthritis of the knee treated with or without intraarticular corticosteroid injections. Bull Hosp Jt Dis 1993; 53:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/33\">",
"      Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage 1993; 1:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/34\">",
"      Williams JM, Brandt KD. Triamcinolone hexacetonide protects against fibrillation and osteophyte formation following chemically induced articular cartilage damage. Arthritis Rheum 1985; 28:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/35\">",
"      Pelletier JP, Mineau F, Raynauld JP, et al. Intraarticular injections with methylprednisolone acetate reduce osteoarthritic lesions in parallel with chondrocyte stromelysin synthesis in experimental osteoarthritis. Arthritis Rheum 1994; 37:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/36\">",
"      Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the knee: meta-analysis. BMJ 2004; 328:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/37\">",
"      Lambert RG, Hutchings EJ, Grace MG, et al. Steroid injection for osteoarthritis of the hip: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2007; 56:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/38\">",
"      Meenagh GK, Patton J, Kynes C, Wright GD. A randomised controlled trial of intra-articular corticosteroid injection of the carpometacarpal joint of the thumb in osteoarthritis. Ann Rheum Dis 2004; 63:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/39\">",
"      Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003; 48:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/40\">",
"      Gatter RA, Andrews RP, Cooley DA, et al. American college of rheumatology guidelines for performing office synovial fluid examinations. J Clin Rheumatol 1995; 1:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/41\">",
"      Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003; 290:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/42\">",
"      Arrich J, Piribauer F, Mad P, et al. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 2005; 172:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/43\">",
"      Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998; 25:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/44\">",
"      Felson DT, Anderson JJ. Hyaluronate sodium injections for osteoarthritis: hope, hype, and hard truths. Arch Intern Med 2002; 162:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/45\">",
"      Pullman-Mooar, S, Mooar, P, Sieck, M, et al. Are there distinctive inflammatory flares of synovitis after hylan GF intra-articular injections? (abstract). Arthritis Rheum 1999; 42(Suppl 9):S295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/46\">",
"      Lussier A, Cividino AA, McFarlane CA, et al. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996; 23:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/47\">",
"      George E. Intra-articular hyaluronan treatment for osteoarthritis. Ann Rheum Dis 1998; 57:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/48\">",
"      Leopold SS, Redd BB, Warme WJ, et al. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. A prospective, randomized trial. J Bone Joint Surg Am 2003; 85-A:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/49\">",
"      Raynauld, JP, Olszynski, WP, Goldsmith, CH, et al. Effectiveness and safety of hylan G-F 20 compared to steroid injections in patients with knee arthritis (abstract). Arthritis Rheum 2003; 48:S484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/50\">",
"      J&uuml;ni P, Reichenbach S, Trelle S, et al. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum 2007; 56:3610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/51\">",
"      Reichenbach S, Blank S, Rutjes AW, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum 2007; 57:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/52\">",
"      Conrozier T, Bertin P, Mathieu P, et al. Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open-label, multicentre, pilot study. Clin Exp Rheumatol 2003; 21:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/53\">",
"      Migliore A, Tormenta S, Martin LS, et al. Open pilot study of ultrasound-guided intra-articular injection of hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis. Clin Rheumatol 2005; 24:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/54\">",
"      Pasquali Ronchetti I, Guerra D, Taparelli F, et al. Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis. Rheumatology (Oxford) 2001; 40:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/55\">",
"      Bellamy N, Campbell J, Robinson V, et al. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006; :CD005328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/56\">",
"      Intra-articular injections for osteoarthritis of the knee. Med Lett Drugs Ther 2006; 48:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/57\">",
"      Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/58\">",
"      Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010; 69:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/59\">",
"      Wandel S, J&uuml;ni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341:c4675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/60\">",
"      Setnikar I, Pacini MA, Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 1991; 41:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/61\">",
"      Biggee BA, Blinn CM, McAlindon TE, et al. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis 2006; 65:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/62\">",
"      Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; :CD002946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/63\">",
"      Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 2007; 56:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/64\">",
"      Reginster JY. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 2007; 56:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/65\">",
"      Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/66\">",
"      Mazzuca SA, Brandt KD, Lane KA, Katz BP. Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum 2002; 46:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/67\">",
"      Pavelk&aacute; K, Gatterov&aacute; J, Olejarov&aacute; M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/68\">",
"      Rozendaal RM, Koes BW, van Osch GJ, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med 2008; 148:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/69\">",
"      Rozendaal RM, Uitterlinden EJ, van Osch GJ, et al. Effect of glucosamine sulphate on joint space narrowing, pain and function in patients with hip osteoarthritis; subgroup analyses of a randomized controlled trial. Osteoarthritis Cartilage 2009; 17:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/70\">",
"      Cibere J, Kopec JA, Thorne A, et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum 2004; 51:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/71\">",
"      Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/72\">",
"      Klashman DJ, Moreland LW, Ike RW, Kalunian KC. Occult presence of CPPD crystals in patients undergoing arthroscopic knee irrigation for refractory pain related to osteoarthritis (abstract). Arthritis Rheum 1994; 37:S240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/73\">",
"      Roberge CJ, Gaudry M, de M&eacute;dicis R, et al. Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 1993; 92:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/74\">",
"      Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol 1986; 13:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/75\">",
"      Das SK, Ramakrishnan S, Mishra K, et al. A randomized controlled trial to evaluate the slow-acting symptom-modifying effects of colchicine in osteoarthritis of the knee: a preliminary report. Arthritis Rheum 2002; 47:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/23/14714/abstract/76\">",
"      Bryant LR, des Rosier KF, Carpenter MT. Hydroxychloroquine in the treatment of erosive osteoarthritis. J Rheumatol 1995; 22:1527.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5501 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14714=[""].join("\n");
var outline_f14_23_14714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Consultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANALGESICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Opioid analgesics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NONSTEROIDAL ANTIINFLAMMATORY DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oral NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Topical NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Choice of NSAID",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INTRAARTICULAR GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INTRAARTICULAR HYALURONANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Knee",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Comparison to intraarticular placebo",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Comparison to NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Comparison to intraarticular glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103700731\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Does molecular weight matter?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25241134\">",
"      GLUCOSAMINE AND CHONDROITIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COLCHICINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ANTIMALARIAL DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5501\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5501|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/25/26015\" title=\"algorithm 1\">",
"      Treatment of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5501|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24431\" title=\"table 1\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7607?source=related_link\">",
"      Acupuncture for rheumatic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7513?source=related_link\">",
"      Complementary and alternative remedies in rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=related_link\">",
"      Investigational approaches to the pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28564?source=related_link\">",
"      Joint aspiration or injection in adults: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=related_link\">",
"      NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=related_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=related_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35335?source=related_link\">",
"      Risk factors for and pathogenesis of analgesic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=related_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=related_link\">",
"      Unusual causes of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_23_14715="Dosing and administration of tetracyclines";
var content_f14_23_14715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing and administration of tetracyclines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Drug",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxycycline",
"       </td>",
"       <td>",
"        100 mg IV/PO every 12 hours; No adjustment in renal dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Tetracycline",
"       </td>",
"       <td>",
"        250-500 mg PO every 6 hours with normal renal function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        250-500 mg PO every 12 to 24 hours with CrCl 10-50 mL/min.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not recommended when CrCl &lt;10 mL/min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minocycline",
"       </td>",
"       <td>",
"        100 mg PO every 12 hours; No adjustment in renal dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demeclocycline",
"       </td>",
"       <td>",
"        150-300 mg PO every 12 to 24 hours; Avoid use in renal dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tigecycline",
"       </td>",
"       <td>",
"        100 mg initial dose then 50 mg IV every 12 hours; No adjustment in renal dysfunction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14715=[""].join("\n");
var outline_f14_23_14715=null;
var title_f14_23_14716="Causes of acquired hypocomplementemia";
var content_f14_23_14716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acquired causes of low complement values",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cases",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of total",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parvovirus infection",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhematoid arthritis associated vasculitis",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver failure*",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune hemolytic anemia",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgG",
"        <sub>",
"         4",
"        </sub>",
"        -positive multiorgan lymphoproliferative syndrome",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryoglobulinemia",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Membranoproliferative glomerulonephitis",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute glomerulonephritis",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune pancreatitis",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The table depicts various causes of acquired hypocomplementemia and the relative frequency of each disorder in a study of 121 Japanese patients. Patients had to have a low C4, C3, and THC to be included. A cause was determined in 111. By requiring both a low C4 and C3, the authors selected for patients with classical pathway activation. This summary is consistent with the experience of one of the authors (JPA), who sees adult patients. The antiphospholipid syndrome is also commonly associated with low C4 and C3 (in the presence or absence of SLE).",
"    <div class=\"footnotes\">",
"     * Mechanism of hypocomplementemia in this situation is reduced hepatic synthesis while the others represent accelerated consumption.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Saeki T, Ito T, Yamazaki H, et al. Hypocomplementemia of unknown etiology: an opportunity to find cases of IgG4-positive multi-organ lymphoproliferative syndrome. Rheumatol Int 2009; 30:99.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14716=[""].join("\n");
var outline_f14_23_14716=null;
var title_f14_23_14717="The Chicago Classification of esophageal motility";
var content_f14_23_14717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Esophageal motility classification on the basis of pressure topography criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CFV &lt;8 cm/s in &gt;90 percent of swallows",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DCI &lt;5000 mmHg s cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal EGJ pressure (10 to 35 mmHg) and deglutitive relaxation (eSleeve 3-s nadir &lt;15 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Peristaltic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild: &ge;3 and &lt;7 swallows with either failed peristalsis or a &ge;2-cm defect in the 30 mmHg isobaric contour of the distal esophageal segment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe: &ge;7 swallows with either failed peristalsis or a &ge;2-cm defect in the 30 mmHg isobaric contour of the distal esophageal segment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Aperistalsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        No continuous pressure domain above an isobaric contour of 30 mmHg in the distal esophageal segment in any swallow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Scleroderma pattern: no continuous pressure domain above an isobaric contour of 30 mmHg in the distal esophageal segment in any swallow and a mean LES pressure &lt;10 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypertensive peristalsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CFV &lt;8 cm/s in &gt;90 percent of swallows",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Mean DCI: &gt;5000 mmHg s cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Nutcracker: mean DCI &gt;5000 and &lt;8000 mmHg s cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Segmental Nutcracker: mean DCI &gt;5000 with only one segmental focus of hypertensive contraction (&gt;180 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Spastic Nutcracker: mean DCI &gt;8000 mmHg s cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Nutcracker LES: mean DCI &gt;5000 mmHg s cm with the focus of hypertensive contraction (&gt;180 mmHg) limited to the LES after-contraction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rapidly propagated pressurization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        CFV &gt;8 cm/s in &ge;20 percent of swallows",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Spasm (increased CFV attributable to rapid contractile wavefront)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Compartmentalized pressurization (increased CFV attributable to distal compartmentalized esophageal pressurization)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abnormal LES tone (end expiratory)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotensive: mean &lt;10 mmHg with normal peristaltic function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertensive: mean &gt;35 mmHg with normal peristaltic function and EGJ relaxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Achalasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired deglutitive EGJ relaxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Aperistalsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Classic: aperistalsis or pan-esophageal pressurization with no identifiable segmental contractile activity with all swallows",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Vigorous: with distal spasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Functional obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Impaired deglutitive EGJ relaxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Mild: CFV &lt;8 cm/s in &gt;90 percent of swallows with a mild elevation (15 to 30 mmHg) of distal esophageal pressurization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Severe: CFV &gt;8 cm/s in &ge;20 percent of swallows with compartmentalized pressurization",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CFV: contractile front velocity, cm/second; DCI: distal contractile integral (quantifies the strength of the contractions in the distal esophagus by integrating the length, contractile amplitude, and duration of a contraction), mmHg sec cm; EGJ: esophagogastric junction; LES: lower esophageal sphincter.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kahrilas PJ, Ghosh SK, Pandolfino JE. Esophageal motility disorders in terms of pressure topography: The Chicago Classification. J Clin Gastroenterol 2008; 42:627. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14717=[""].join("\n");
var outline_f14_23_14717=null;
var title_f14_23_14718="CRP, cholesterol, and future MI risk";
var content_f14_23_14718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Association between cholesterol, C-reactive protein, and risk of myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 257px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among healthy men, the relative risk of a first myocardial infarction (MI) is associated with the total cholesterol/HDL-cholesterol ratio and the level of C-reactive protein (CRP). The figures in the vertical bars are the values of relative risk for each stratum of cholesterol ratio and CRP. The baseline CRP level was predictive of risk for those with medium and high total cholesterol/HDL-cholesterol ratios.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ridker PM, Glynn RJ, Hennekens CH, Circulation 1998; 97:2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_23_14718=[""].join("\n");
var outline_f14_23_14718=null;
var title_f14_23_14719="Contents: Lung cancer";
var content_f14_23_14719=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Lung cancer",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Lung cancer",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Diagnosis and staging",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/17/8474\">",
"           Clinical presentation and management of thymoma and thymic carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/43/17080\">",
"           Computed tomographic and positron emission tomographic scanning of pulmonary nodules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/31/14841\">",
"           Diagnosis and staging of non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44537\">",
"           Diagnostic evaluation and management of the solitary pulmonary nodule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/0/21511\">",
"           Fluorescence bronchoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6759\">",
"           Multiple primary lung cancers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/61/13273\">",
"           Overview of the initial evaluation, treatment and prognosis of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/57/16282\">",
"           Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/35/42552\">",
"           Pathobiology and staging of small cell carcinoma of the lung",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/10/19625\">",
"           Role of imaging in the staging of non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28586\">",
"           Screening for lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/28/28102\">",
"           Thoracic positron emission tomography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/35/3642\">",
"           Transbronchial needle aspiration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/21/44373\">",
"           Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Etiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/0/12298\">",
"           Cigarette smoking and other risk factors for lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10072\">",
"           Women and lung cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mediastinal tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/40/32392\">",
"           Anterior mediastinal mass lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/24/31111\">",
"           Evaluation of mediastinal masses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/52/10058\">",
"           Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/43/4794\">",
"           Pathology of mediastinal tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mesothelioma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/50/32552\">",
"           Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7622\">",
"           Epidemiology of malignant mesothelioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29204\">",
"           Pathology of malignant pleural mesothelioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/21/42329\">",
"           Systemic treatment for unresectable malignant pleural mesothelioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/41/28312\">",
"           Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/45/9946\">",
"           Bronchioloalveolar carcinoma, including adenocarcinoma in situ",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/44/8902\">",
"           Chemoprevention of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12394\">",
"           Lung cancer in never smokers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/24/23945\">",
"           Nonresolving pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/58/14250\">",
"           Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9750\">",
"           Pulmonary manifestations of HIV-associated lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/36/10821\">",
"           Tracheal tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/43/22201\">",
"           Pathology of lung malignancies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/28/21962\">",
"           Thymic neuroendocrine (carcinoid) tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/26/17833\">",
"           Adjuvant systemic therapy in resectable non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/34/9768\">",
"           Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/0/34823\">",
"           Airway stents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/31/40440\">",
"           Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/25/38292\">",
"           Bronchoscopic cryosurgery: Indications, contraindications, and outcomes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/13/10453\">",
"           Bronchoscopic cryosurgery: Principles and technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/47/38645\">",
"           Bronchoscopic laser resection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/43/9914\">",
"           Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/17/8474\">",
"           Clinical presentation and management of thymoma and thymic carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/26/20900\">",
"           Cryoablation of lung tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37351\">",
"           Diagnosis and management of central airway obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/18/32038\">",
"           Endobronchial brachytherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/11/11447\">",
"           Endobronchial electrocautery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/47/8951\">",
"           Experimental approaches to treatment for small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/52/10058\">",
"           Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/39/6778\">",
"           First-line chemotherapy for patients with extensive stage small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/54/34666\">",
"           Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/4/31816\">",
"           Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/6/13416\">",
"           Management of malignant pleural effusions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/5/1114\">",
"           Management of stage I and stage II non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/36/39498\">",
"           Management of stage III non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6759\">",
"           Multiple primary lung cancers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/57/16282\">",
"           Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/57/21401\">",
"           Overview of the treatment of advanced non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/58/14250\">",
"           Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14809\">",
"           Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/55/37749\">",
"           Photodynamic therapy of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/2/15400\">",
"           Preoperative evaluation for lung resection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/50/1830\">",
"           Prophylactic cranial irradiation for patients with small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/42/25255\">",
"           Radiofrequency ablation of lung tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/36/38469\">",
"           Role of surgery in multimodality therapy for small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/36/40520\">",
"           Second-line therapy for patients with previously treated advanced non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32329\">",
"           Sequelae and complications of pneumonectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/47/17143\">",
"           Stereotactic body radiation therapy for primary and metastatic lung tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/38/36455\">",
"           Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/37/26199\">",
"           Systemic therapy for poor performance status patients with advanced non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/5/4183\">",
"           Treatment of refractory and relapsed small cell lung cancer",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-867536E9C0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f14_23_14719=[""].join("\n");
var outline_f14_23_14719=null;
